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Abstract

MicroRNA 1207-3p in Prostate Cancer
by
Dibash K. Das

Advisor: Dr. Olorunseun O. Ogunwobi

Prostate cancer (PCa) is the most commonly diagnosed male cancer and the second leading cause
of cancer-related death for men in the United States. Understanding the molecular mechanisms
involved in progression from the asymptomatic androgen-dependent PCa to the lethal castration
resistant prostate cancer (CRPC) is a major challenge. MicroRNAs (miRNAs), are known to be
dysregulated in PCa. MicroRNA-1207-3p (miR-1207-3p) is encoded by the non-protein coding
gene locus PVT1 on the 8q24 human chromosomal region, an established PCa susceptibility locus.
However, the role of miR-1207-3p in PCa is unclear. We have discovered that miR-1207-3p is
significantly underexpressed in PCa cell lines compared to normal prostate epithelial cells.
Moreover, the increased expression of miR-1207-3p in PCa cells significantly inhibits
proliferation, migration, and induces apoptosis via direct molecular targeting of Fibronectin type
III domain containing 1 (FNDC1) and consequent loss of expression of fibronectin (FN1), and
consequent loss of expression of the androgen receptor (AR). PCa cell lines and patient-derived
tissues revealed significant overexpression of FNDC1, FN1 and AR which are factors that
positively correlate with aggressive PCa. Also, metastatic PCa displayed concurrent
overexpression of FNDC1, FN1 and AR. Taken together, this is the first description of a novel
miR-1207-3p/FNDC1/FN1/AR regulatory pathway in PCa. For the unbiased discovery of the
molecular targets of miR-1207-3p, we designed and synthesized a novel synthetic biotinylated
iv

miR-1207-3p duplex (NB1207), and a novel synthetic biotinylated scramble duplex (NB1). We
observed that NB1207, but not the scrambled duplex NB1, directly targets the 3’UTR of FNDC1
and more effectively inhibits proliferation, inhibits migration and increases apoptosis of PCa cells
including those aggressively tumorigenic. Interestingly, the location of miR-1207-3p on the 8q24
human chromosomal region is downstream of the proto-oncogene, c-MYC. c-MYC has been
linked to castration resistant prostate cancer (CRPC). However, the mechanisms regulating c-MYC
remain unclear in CRPC. In this study, we discovered that c-MYC is regulated and therapeutically
targetable via the miR-1207-3p/FNDC1/FN1/AR pathway in CRPC. miR-1207-3p negatively
correlates with c-MYC in prostate tumors with Gleason score ≥8. Additionally, we discovered that
overexpression of miR-1207-3p significantly inhibited proliferation and increased apoptosis in
CRPC cells. We also compared the efficacy of NB1207 and NB5, two novel synthetic analogs of
miR-1207-3p, with the currently used therapies against CPRC: abiraterone, enzalutamide, and
apalutamide (phase 3 clinical trial). Treatment with NB1207 and NB5 resulted in increased
inhibition of AR-V7 protein expression, and more significant inhibition of proliferation and
increases in apoptosis of CRPC cells compared to abiraterone, enzalutamide and apalutamide.
These results demonstrate that synthetic analogs of miR-1207-3p, such as NB5 and NB1207, may
be a novel strategy for successful therapeutic targeting of c-MYC via the miR-12073p/FNDC1/FN1/AR pathway in CRPC. In summary, the present study indicates that miR-12073p may have potential diagnostic, prognostic, and therapeutic applications in PCa.

v

Acknowledgements

I would like to express my sincere gratitude to my mentor and advisor Dr. Olorunseun Ogunwobi
for his endless guidance and motivation throughout the years. He has always set the bar high, and
pushed me to always strive to achieve more than I thought possible. More specifically, I fondly
recall the many sessions in his office where he offered thoughtful advice on both science, career
choices and life. I am truly grateful to Dr. Ogunwobi as his mentorship helped me grow into a
better scientist and person.

I would also like to thank my committee members, Dr. Frida Kleiman, Dr. Nancy Greenbaum, Dr.
Brian Robinson, & Dr. Joseph Osborne for their encouragement and advice during this journey. I
am truly appreciative.

I would also like to thank all of the members of the Ogunwobi lab who have shared in this journey
with me. Special thanks to Dr. Adeodat Ilboudo, who helped me get through my first year in the
lab. I would also like to thank my labmates who I had a chance to work with and have helped me
with my project: Michelle, Jeannette, Trisheena, Victoria, Jazmine, Anna, Tamara, Fayola, and
Choung. Thank you all.

None of this would have been possible, without the unconditional love, support and blessings of
my parents, Achyut Kumar Das and Kanak Prava Das. Immigrant parents who sacrificed so much
so that I could chase my dreams. Thank you for teaching me the value of hard work that has shaped
who I am. There are not enough words to describe how thankful I am to the both of you. A special
shout out to my sister, Jessica Das. Thank you for always making me laugh as well as being an
vi

inspiration, although you’re the younger sibling! I would also like to thank my father-in-law and
mother-in-law, Bir Singh and Hardeep Kaur. Thank you all for your continuous support and
encouragement.

Finally, a thank you to my dear wife, Ritu Das. You are my will to carry on in the face of the most
difficult times and my wish to succeed. You have been my strongest support. My appreciation for
you knows no bounds.

Chapter 3 in this dissertation is a combination of works published in Experimental Cell Research,
Translational Oncology and RNA & Disease. Chapter 4 is being submitted to Cancer Discovery.

vii

Table of Contents

Abstract…………………………………………………………………………………………..iv
Acknowledgments…………………………………………………………………………….....vi
Table of Contents……………………………………………………………………………....viii
List of Abbreviations……………………………………………………………………………xi
List of Tables……………………………………………………………………………………xii
List of Figures……………………………………………………………………………….…xiii
Chapter 1: Introduction…………………………………………………………………………1
Prostate cancer…………………………………………………………………………………….2
The role of the androgen receptor (AR) and AR-V7 in prostate cancer………….……………….3
Role of microRNAs in cancer……….…………………………………………………………….4
The role of microRNA-1207-3p in prostate cancer………………………………………………..6
FNDC1 and FN1 regulation by the miR-1207-3p pathway in prostate cancer……………………6
c-MYC regulation by the miR-1207-3p pathway in prostate cancer……………………………….7
Clinical significance of miR-1207-3p in prostate cancer…………………………………………..7
Racial disparity in prostate cancer…………………………………………………………………8
Chapter 2: Materials and Methods………………………………………………………...…..10
Cells and cell culture conditions…………………………………………………………….....…11
Transfection of oligonucleotide inhibitor and mimic of miR-1207-3p……………………..……12
Transfection of siRNA………………………………………………………………………..….12
RNA isolation and quantitative real-time polymerase chain reaction (qPCR) analysis……….…13
Click-iT EdU Alexa Fluor 488 Imaging Kit……………………………………………………..13

viii

Annexin V Assay…………………………………………………………………………………13
Luciferase reporter assay…………………………………………………………………………14
Western blot analysis………………………………………………………………………….….14
RNA pulldown assay…………………………………………………………………………..…15
Patients and samples……………………………………………………………………………...15
Statistical Analysis…………………………………………………………………….…………17
Chapter 3: miR-1207-3p regulates the androgen receptor in prostate cancer via
FNDC1/FN1………………………………………………………………………..……………19
Introduction………………………………………………………………………………………20
Results……………………………………………………………………………………………21
miR-1207-3p is significantly underexpressed in PCa cells………………………………21
Overexpression of miR-1207-3p suppresses endogenous expression of fibronectin type III
domain containing 1 (FNDC1) and fibronectin (FN1) in PCa cells………………………23
miR-1207-3p directly targets FNDC1……………………………………………………24
miR-1207-3p regulates FN1 via FNDC1…………………………………………………26
FNDC1 regulates proliferation, apoptosis, and migration of PCa cells…………………..27
FN1 regulates proliferation, apoptosis and migration of PCa cells……………………….30
miR-1207-3p regulates the androgen receptor via FNDC1/FN1…………………...…….32
FNDC1, FN1, and AR expression are positively correlated in human prostate cancers and
upregulation is associated with aggressive disease……………………………………….34
miR-1207-3p is differentially expressed in PCa in men of African ancestry compared to
Caucasian men…………………….……………………………………………….…….36
miR-1207-3p regulates migration, apoptosis and proliferation of PCa cells……….……37
Discussion…………………………………………………………………………………..……40
Author contributions……………………………………………………………………………45

ix

Acknowledgements……………………………………………………………………………....45
Human and animal rights…………………………………………………………………………45
Chapter 4: c-MYC is regulated and therapeutically targetable via the miR-12073p/FNDC1/FN1/AR pathway in castration resistant prostate cancer…………………..……46
Introduction………………………………………………………………………………………47
Results……………………………………………………………………………………………49
Underexpression of miR-1207-3p and the overexpression of FNDC1, FN1, AR and c-MYC
are significantly associated with aggressive prostate cancer………………………..…...49
miR-1207-3p negatively correlates with c-MYC in prostate tumors with Gleason score
≥8………………………………………………………………………...………………53
c-MYC is downstream of the novel miR-1207-3p/FNDC1/FN1/AR pathway……….…54
A novel synthetic analog of miR-1207-3p, NB1207, significantly inhibits c-MYC
expression in CRPC cells…………………………………………..………………….…57
NB1207 significantly inhibits migration, inhibits proliferation and induces apoptosis in
CRPC cells………………………………………………………………………...……..59
NB1207 and NB5 inhibits AR-V7 expression and is more effective in inhibiting
proliferation and apoptosis in CRPC cells compared to enzalutamide, abiraterone and
apalutamide……………………………………………………………………….….…..60
Discussion………………………………………………………………………………………..65
Author contributions……………………………………………………………………………69
Acknowledgements……………………………………………………………………………....69
Chapter 5: Conclusion, Significance and Future Directions…………………………………70
Chapter 6: Bibliography………………………………………………………………………..76

x

List of Abbreviations

ADT

Androgen deprivation therapy

AR

Androgen receptor

AR-V7

Androgen receptor variant 7

CM

Caucasian men

CRPC

Castration resistant prostate cancer

FN1

Fibronectin

FNDC1

Fibronectin type III domain containing 1

GWAS

Genome-wide association studies

lncRNA

long non-coding RNA

miRNA

microRNA

miR-1207-3p

microRNA-1207-3p

NB1

biotinylated scramble duplex

NB2

scramble duplex

NB3

biotinylated mutant duplex

NB4

mutant duplex

NB5

miR-1207-3p duplex

NB1207

biotinylated miR-1207-3p duplex

moAA

men of African Ancestry

PCa

Prostate Cancer

PSA

prostate specific antigen

PVT1

plasmacytoma variant translocation 1 gene

qRT-PCR

real-time quantitative reverse transcription polymerase chain reaction

UTR

untranslated region

xi

List of Tables

Table 3.1: Fibronectin expression in prostate cancer tissues of 377 patients………………...35
Table 3.2: miR-1207-3p is differentially expressed between moAA and CM……………….37

xii

List of Figures

Figure 3.1: miR-1207-3p expression is lost in prostate cancer cells, and effect of an
oligonucleotide inhibitor and oligonucleotide mimic of miR-1207-3p on miR-1207-3p
expression…………………………………………………………………………………….….22
Figure 3.2: FNDC1 is a direct molecular target of miR-1207-3p………………………….…25
Figure 3.3: miR-1207-3p regulates FN1 expression…………………………………………..27
Figure 3.4: Effect of siRNA knockdown of FNDC1………………………………………..…29
Figure 3.5: Effect of siRNA knockdown of fibronectin…………………………………….…31
Figure 3.6: miR-1207-3p/FNDC1/FN1/AR is a regulatory pathway in prostate cancer…….33
Figure 3.7: FNDC1, FN1, and AR expression is correlated in prostate cancers and
upregulation is associated with aggressive disease…………………………………………….36
Figure 3.8: Loss of miR-1207-3p expression promotes migration, proliferation and inhibits
apoptosis…………………………………………………………………………………..…….39
Figure 3.9: A novel miR-1207-3p/FNDC1/FN1/AR regulatory pathway in prostate cancer..44
Figure 4.1: c-MYC has been linked to prostate cancer aggressiveness………………………48
Figure 4.2: Underexpression of miR-1207-3p is significantly associated with aggressive
prostate cancer………………………………………………………………………………….51
Figure 4.3: Overexpression of FNDC1, FN1, and AR are significantly associated with
aggressive prostate cancer………………………………………………………………….…. 52
Figure 4.4: Overexpression of c-MYC are significantly associated with aggressive prostate
cancer………………………………………………………………………………………...….53

xiii

Figure 4.5: miR-1207-3p negatively correlates with c-MYC in tumors with Gleason score
≥8……………………………………………………………………………………………..….54
Figure 4.6: c-MYC is not a direct molecular target of miR-1207-3p but is regulated by the
miR-1207-3p/FNDC1/FN1/AR pathway………………………………………………..……..56
Figure 4.7: A novel miR-1207-3p/FNDC1/FN1/AR/c-MYC pathway in CRPC in which
NB1207 significantly inhibits c-MYC expression in CRPC cells……………………………..58
Figure 4.8: NB1207 significantly inhibits migration, inhibits proliferation and induces
apoptosis in CRPC cells………………………………………………………………...………60
Figure 4.9: NB1207 and NB5 inhibits AR-V7 expression and is more effective in inhibiting
proliferation

in

CRPC

cells

compared

to

enzalutamide,

abiraterone

and

apalutamide…………………………………………………………………………….……….63
Figure 4.10: NB1207 and NB5 is more effective in increasing apoptosis in CRPC cells
compared to enzalutamide, abiraterone and apalutamide…………………….……..………64
Figure 5.1: miR-1207-3p/FNDC1/FN1/AR/c-MYC is a novel regulatory pathway in prostate
cancer…………………………………………………………………………...……………….75

xiv

Chapter 1:
Introduction

1

Prostate cancer
Prostate cancer (PCa) is the most commonly diagnosed cancer among males in the western world13

. Accounting for 180,890 new cases in the US in 2016, PCa is a major cause of cancer morbidity

and mortality 4-6,7. The annual morbidity grows as the rate of PCa has increased by 14% over the
last two decades3,6,8,9. One of the challenges faced in combating PCa is its considerable
heterogeneity1,9,10. Typically, early PCa is asymptomatic, and advanced PCA is associated with
the appearance of symptoms such as blood in the urine, burning/pain during urination and
metastasis to the bones11-13. Active research continues in the areas of early detection and treatment
of PCa, but these efforts have met obstacles. The current screening tool for PCa, prostate specific
antigen (PSA), is highly controversial as it is not PCa-specific and has a high false positive rate14,15.
This poor correlation leads to adverse consequences associated with unnecessary diagnosis and
overtreatment of non-aggressive PCa14-16. Unfortunately, treatments are highly aggressive,
invasive, costly and may impact a man’s long-term quality of life due to complications or severe
side effects12,17,18.

Effective methods for early detection of clinically relevant PCa are crucial and should minimize
unnecessary, aggressive treatments and cancer-related deaths. Currently, there are no satisfactory
biomarkers available that are both effective for the early detection of PCa and sensitive enough to
discriminate between indolent and aggressive PCa1,13,19. Understanding the molecular mechanisms
underlying the development of PCa is necessary for the discovery of novel and efficacious
biomarkers which offer specificity and improve risk stratification and treatment outcomes for
patients.
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The role of AR and AR-V7 in prostate cancer
The Androgen hormone stimulates and controls the development and maintenance of male
characteristics by binding to AR20,21. The AR, a member of the steroid hormone receptor
superfamily, contains 8 canonical exons encoded in four functional domains17,22,23. The domains
include the NH2-terminal transactivation domain (NTD), the DNA-binding domain (DBD), the
hinge region, and the ligand-binding domain (LBD)17,22,23. The AR carries out its cellular functions
as a ligand-activated transcription factor17,22,23. However, PCa is an androgen-driven disease and
the androgen receptor (AR) plays a critical role in the development and progression of PCa17,20,21.
PCa typically starts as androgen-dependent and most men are responsive to medical and surgical
androgen deprivation therapies (ADT)12,17,21,24,25. However, in spite of these efforts, the cancer
inevitably reoccurs in up to 30% of men, who progress to androgen-independent PCa also known
as castration-resistant PCa (CRPC)6,12,17,21. It is this highly aggressive form of PCa that is
lethal17,21,24.

The therapeutic options for advanced PCa are limited, and minimally effective

12,26,27

. Current

CRPC anti-androgen therapies such as abiraterone, enzalutamide and apalutamide have focused
on the androgen-dependent activation of AR through its ligand-binding domain (LBD)20,22,28.
Unfortunately, several studies have shown that androgen receptor variants (AR-Vs) which lack the
LBD are resistant to these LBD-targeting AR antagonists or agents that repress androgen
biosynthesis22,28-30. AR-V7 is the most abundant and the most studied member because it is the
only known variant of which the encoded endogenous protein is detectable in clinical
specimens22,28,30,31. AR-V7 contains the first three canonical exons of the AR, however AR-V7 is
followed by variant-specific cryptic exon 3 (CE3) within intron 3 which prematurely truncates the
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AR in a manner that deletes exons 4-828,30,32. These deleted exons normally code for the hinge
region and LBD29-31. Consequently, AR-V7 remains constitutively active as a transcription factor,
independent of androgen signaling28-30. Furthermore, studies have shown that the detection of ARV7 in PCa has been correlated with CRPC and resistance against enzalutamide and
abiraterone22,28,30. Consequently, although the mechanism is not fully understood, the androgen
receptor (AR) along with AR-V7 are considered important targets for CRPC therapy12,17,25.

Role of microRNAs in cancer
MicroRNAs (miRNAs) are small (18-22 nucleotides) non-protein coding regulatory RNAs, which
play an essential role in post-transcriptional gene regulation27,33-35. The canonical biogenesis
of miRNAs in vertebrate and invertebrate cells involves two key processing steps35-37. In the
nucleus, the RNase III enzyme complex Drosha, cleaves long primary miRNA transcripts (pri
-miRNA) containing one or more hairpin structures to yield stem-loop precursor miRNAs (pre
-miRNA) that are approximately 55-70 nucleotides in length35-37. These pre-miRNAs are then
exported to the cytoplasm where they are subsequently cleaved by another RNase III enzyme,
Dicer, to remove the loop structure to produce a mature miRNA35-37.

MicroRNAs are conserved, endogenously synthesized and have been shown to regulate the
expression of nearly 60% of human genes by regulating many biological processes including
proliferation, migration and apoptosis27,33-36,38. Consequently, miRNAs possess great potential as
ideal therapeutic tools for human cancers7,35,39. The canonical mechanism of miRNA targeting
involves an interaction between the 5’ end of the miRNA called the ‘seed region’ (from nucleotides
2 to 8) and the 3’ untranslated region (3’ UTR) of the mRNA35-37. The seed region is the most
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conserved region of miRNAs, and in many instances a seed match alone is sufficient to confer
mRNA recognition, which results in the suppression of protein translation35-37. In the case of
perfect complementarity between the miRNA and the mRNA target site, the mRNA is degraded3537

. However, because high complementarity is not required for miRNA regulation on an mRNA, a

single miRNA can target multiple genes35-37.

An abundant body of data has demonstrated that miRNA expression are found to be aberrant in
many cancers including PCa4,34,40,41. Many miRNAs’ expression reflect the tumor of origin,
functioning as either oncogenes or tumor suppressors according to the roles of their target genes
which strongly supports their use as therapeutic tools for cancer management33,40,42. Since miRNA
expression profiles may serve as “unique signature” in classifying human cancers, they have
potential to be used for effective early detection and prognostic biomarkers in PCa as well8,34,43,44.
Several recently discovered miRNAs based on serum, tumor, blood, urine and tissue-derived
samples obtained from human patients from various cancers have demonstrated the stability and
robustness of miRNAs to serve as clinical biomarkers7,8,34,43,45,46. A biomarker that reliably
discriminates/distinguishes indolent from aggressive PCa is useful for treatment stratification.
Aggressive treatment may be initiated early in rapidly lethal PCa while unnecessary for otherwise
indolent PCa. Furthermore, it raises the potential for successful miRNA based therapy. Ultimately,
few reports describe the role of miRNAs in PCa aggressiveness, highlighting the need for
understanding of which specific miRNAs directly regulating PCa and by which mechanisms7,34.

5

The role of miRNA-1207-3p in prostate cancer
It is now well-known that the 8q24 human chromosomal locus has profound genomic instability
in PCa2,47-50. Several studies, including one published recently from our lab, have shown that the
300kb long non-protein coding gene locus, PVT1, located on the 8q24 chromosomal locus, is
dysregulated in PCa47. PVT1 has at least 12 different exons and encodes six microRNAs,
including microRNA-1207-3p (miR-1207-3p)1,47,50,51.

Five of the six miRNAs are not associated with annotated PVT1 exons, rather they are intronic,
including miR-1207-3p1,47. However, no study has been performed on the status and biological
functions of miR-1207-3p in PCa to date. Our study is the first to determine the role of miR-12073p in PCa1. To explore the molecular mechanisms through which miR-1207-3p exerts its PCa, the
molecular targets of miR-1207-3p must be identified. No studies have ever shed light on the direct
molecular targets of miR-1207-3p in any system. To investigate this, synthetic biotinylated analogs
of miR-1207-3p were designed and synthesized1.

FNDC1 and FN1 regulation by the miR-1207-3p pathway in prostate cancer
We identified Fibronectin type III domain containing 1 (FNDC1) as a putative molecular target
of miR-1207-3p. FNDCI contains the conserved ‘Fibronectin type III domain’ of Fibronectin
(FN1)52-55. FN1 is a glycoprotein consisting of three domains56-58. These FN1 domains (type I,
type II and type III), have undergone exon shuffling resulting in their abundance in other
molecules54,59,60. FN1 has been implicated in carcinogenesis and known to be a regulator of cell
migration, proliferation and apoptosis61-64. So far, only two miRNAs have been shown to directly
target a member of the FN1 family in PCa, miRs-143 and-145, which are both downregulated in
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PCa cell lines and tissues65,66. However, these studies did not reach a consensus on their effects
on FN134,65,67

The biological function of FNDC1 has not been well studied. The FNDC1 gene is located on the
6q25.3 human chromosomal region52,68. The limited data available on FNDC1 reports that
FNDC1 has also been associated with prostate leiomyosarcoma 94,69. Prostate leiomyosarcoma is
a mesenchymal tumor that is particularly rare, highly aggressive, and accounts for less than 3.7%
of primary prostate diseases69,70. However, a functional role for FNDC1 in PCa has not been
reported. Our study is the first to demonstrate a microRNA regulation of FNDC1.

c-MYC regulation by the miR-1207-3p pathway in prostate cancer
Studies have shown that PVT1/MYC cooperation is a fundamental feature in all cancers with 8q24
amplification and 98% of the 8q24 amplicons contained amplification of both the MYC and PVT1
loci71-74. c-MYC is a proto-oncogene linked to PCa aggressiveness48,71,72,74-76. Furthermore, cMYC has been a consequence of antiandrogen treatment, and has been reported to be downstream
of AR in some PCa71,74,75,77. Interestingly, miR-1207-3p is encoded at the PVT1 gene locus, which
is located downstream of c-MYC on the 8q24 human chromosomal region48,71,72,74,78. Although
miRNAs have also been implicated in the regulation of c-MYC, the mechanisms regulating cMYC remains unclear in PCa79,80. Consequently, we aimed to determine if c-MYC is regulated
and therapeutically targetable via our novel miR-1207-3p pathway.

Clinical significance of miR-1207-3p in prostate cancer
Using our novel analogs, we sought to investigate if miR-1207-3p regulates AR as this may play
a role in the progression from androgen-dependent to the life-threatening castration-resistant
7

prostate cancer (CPRC)5,17,34. At diagnosis, clinical and pathologic features, such as prostate
specific antigen (PSA) level, pathologic Gleason grade, and tumor stage, are used to inform clinical
decision-making8,9,43. The Gleason grading system is used to help evaluate the prognosis of men
with PCa using samples from a prostate biopsy25. To determine if miR-1207-3p can be a useful
non-invasive biomarker in PCa clinical decision-making, we examined the expression levels of
miR-1207-3p and its molecular targets in PCa patients by real-time quantitative reverse
transcription polymerase chain reaction (qRT-PCR), and publicly available gene expression
datasets in the Oncomine database. To assess miR-1207-3p’s ability to improve risk stratification
in human clinical PCa, we analyzed correlation with Gleason scores. Additionally, because CRPC
has been shown to be resistant to current anti-androgen therapies, preventing/treating antiandrogen
resistance is a major clinical challenge. Therefore, we compared the efficacy of NB1207 and NB5,
two novel synthetic analogs of miR-1207-3p, with current anti-AR treatments for CRPC
(abiraterone, enzalutamide and apalutamide) in vitro.

Racial disparity in prostate cancer
For reasons still unclear, men of African ancestry (moAA) have the worlds’ highest incidence of
PCa 47,81-84. MoAA exhibit 19% increased incidence and 37% increased mortality rate from PCa
compared to Caucasian men (CM) and disparities in tumor aggressiveness remain after controlling
for social determinants82-86. Consequently, aggressiveness of PCa may be due to specific biological
factors83,87. To address this high mortality, effective early detection and therapeutic strategies are
needed82,83,87,88. Undoubtedly, miRNAs are dysregulated in PCa85,89. However, miR-1207-3p
expression in PCa in moAA is unknown. Therefore, we investigated the expression of miR-12073p and its molecular targets in PCa cells of moAA by evaluating the expression profile of miR-
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1207-3p, FNDC1, FN1, AR and c-MYC in the prostate tissues in a cohort of West African Black
males. Our study seeks to determine if miR-1207-3p and its molecular targets may be useful in
increasing our understanding of the molecular mechanisms underlying PCa in moAA. Moreover,
such strategies have the prospective to ultimately result in novel diagnostic, prognostic biomarkers
as well as specific approaches for treatment that will help reduce PCa disparities in moAA.

9

Chapter 2:
Materials and Methods

10

Cells and cell culture conditions
Androgen-dependent RWPE-1 cells were cultured in Keratinocyte-Serum free medium (SFM)
supplemented with 0.05 mg/ml bovine pituitary extract (BPE), 5 ng/ml epidermal growth factor
(EGF) and 1% Penicillin-Streptomycin. Androgen-dependent WPE1-NA22 cells were cultured in
Keratinocyte-SFM medium supplemented with 0.05 mg/ml BPE, 5 ng/ml EGF and 1%
Penicillin/Streptomycin. Androgen-dependent MDA PCa 2b cells were cultured in F-12K medium
supplemented with 20% fetal bovine serum, 25 ng/ml cholera toxin, 10 ng/ml mouse Epidermal
Growth Factor, 0.005 mM phosphoethanolamine, 100 pg/ml hydrocortisone, 45 nM selenious acid,
0.005 mg/ml bovine insulin. Androgen-independent PC-3 cells were cultured in F-12K medium
supplemented with 10% Fetal Bovine Serum and 1% Penicillin/Streptomycin. Androgenindependent 22Rv1 cells were cultured in RPMI 1640 supplemented with 10% heat inactivated
FBS, and 1% Penicillin/Streptomycin. RWPE-1, WPE1-NA22, PC-3, MDA PCa 2b and 22RV1
cell lines were purchased from the American Type Culture Collection. Androgen-dependent
LNCaP cells were cultured in RPMI 1640 supplemented with 10% heat inactivated FBS, 1%
Penicillin/Streptomycin and 10nM testosterone. Androgen-independent C4-2B cells were cultured
in DMEM supplemented with 200ml Ham’s F12, 10% heat-inactivated FBS, 1%
Penicillin/Streptomycin, insulin (5µg/ml), triiodothyronine (13.65 pg/ml), human apo-transferrin
(4.4 µg/ml), d-Biotin (0.244 µg/ml), and Adenine (12.5 µg/ml). The C4-2B cell line was obtained
from MD Anderson Cancer Center under a materials transfer agreement with Hunter College of
The City University of New York. Androgen-independent E006AA and E006AA-hT were
cultured in DMEM supplemented with 1% fetal bovine serum and 1% Penicillin/Streptomycin.
E006AA and E006AA-hT were obtained from Dr. Shahriar Koochekpour under a materials
transfer agreement between Roswell Park Cancer Institute and Hunter College of The City
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University of New York1. These cells were cultured at 37C/5% CO2, under humidified
atmosphere.

Transfection of oligonucleotide inhibitor and mimic of miR-1207-3p
Cells were seeded in 6-well plates. After reaching 60% - 70% confluence, media is replaced with
Opti-MEM (Thermo Fisher Scientific Inc; Wilmington, DE, U.S.A) and cells are transfected with
either a 50nM non-targeting negative control oligonucleotide (MISSION® Synthetic microRNA
Negative Control, product# NCSTUD001), 50nM miR-1207-3p oligonucleotide mimic
(MISSION® microRNA Mimic, product# HMI0066), 50nM miR-1207-3p oligonucleotide
inhibitor (MISSION® Synthetic microRNA Inhibitor, human, product# HSTUD0066) (SigmaAldrich, St. Louis, MO, USA), or novel synthetic miRNA-1207-3p duplexes (biotinylated
scramble duplex (NB1), scramble duplex (NB2), biotinylated mutant duplex (NB3), mutant duplex
(NB4), miR-1207-3p duplex (NB5), or biotinylated miR-1207-3p duplex (NB1207), (patent
pending)), using Lipofectamine RNAiMAX (Thermo Fisher Scientific Inc; Wilmington, DE,
U.S.A) according to the manufacturer’s instructions. Transfected cells are then incubated at 37°C
for a total duration of 24 hours before cells are lysated1.

Transfection of siRNA
Cells were transfected with fibronectin, FNDC1, AR or c-MYC siRNAs. Negative control
(scramble) siRNAs which does not lead to specific degradation of any known mRNA was used as
the negative control1.
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RNA isolation and quantitative real-time polymerase chain reaction (qPCR) analysis
RNA isolation and qPCR were performed as previously described

90

. miR-1207-3p and

RNU6_B12 snRNA primers were purchased from (Qiagen, Hilden, Germany). Primers for human
fibronectin mRNA, and, human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA
were custom-designed using OligoPerfect™ Designer (Thermo Fisher Scientific Inc; Wilmington,
DE, U.S.A)1 and purchased through Millipore Sigma (St Louis, U.S.A).

Click-iT EdU Alexa Fluor 488 Imaging Kit
Cells were transfected with either oligonucleotides of miR-1207-3p, negative controls, siRNAs
against FNCD1, FN1, AR or c-MYC as well as synthetic analogs and mutants of miR-1207-3p.
Assay was performed according to manufacturer’s instructions: (Click-iT™ EdU Alexa Fluor™
488 Imaging Kit, Cat. No.: C10337, ThermoFisher Scientific Inc; Wilmington, DE, U.S.A). EdU
is a nucleoside analog of thymidine and is incorporated into DNA during active DNA synthesis.
Detection is based on a click reaction, 2-3 a copper-catalyzed covalent reaction between an azide
and an alkyne. EdU contains the alkyne and Alexa Fluor dye contains the azide. Cells were imaged
and analyzed using the Motic Images Plus 2.0 Software (Motic; British Columbia, Canada) and
positive EdU signal is indicative of S-phase cell population1.

Annexin V Assay
Cells were transfected with either oligonucleotides of miR-1207-3p, negative controls, siRNAs
against FNCD1, FN1, AR or c-MYC as well as synthetic analogs and mutants of miR-1207-3p for
24 hours prior to Annexin V staining. Assay was performed according to manufacturer’s
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instructions: (ApoScreen® Annexin V Apoptosis Kit-FITC, Cat. No. 10010-02, SouthernBiotech
Birmingham, U.S.A). Annexin V and PI staining were analyzed using flow cytometry1.

Luciferase reporter assay
Human FNDC1 and miRNA target clone control vector for pEZX-MT06 were purchased from
GeneCopoeia, Inc, Rockville, MD, USA. Cells were seeded co-transfected with luciferaseexpressing 3’ UTR clones of FNDC1 along with a 50nM miR-1207-3p oligonucleotide mimic. As
the control, cells were also co-transfected with 3’UTR clones of FNDC1 with miR-1207-3p
synthetic non-targeting oligonucleotide negative control. The lysate was analyzed by SpectraMax
i3x multi-mode detection platform1.

Western blot analysis
Western blotting was performed as previously described91. Primary antibodies used were against
human fibronectin: ab2413 (Abcam plc, Cambridge, UK), human FNDC1 (Y-12): sc-107546
(Santa Cruz Biotechnology, TX, U.S.A), human AR: sc-7305 (Santa Cruz Biotechnology, TX,
U.S.A), human c-MYC: ab32072 (Abcam plc, Cambridge, UK), human AR-V7-specific:
ab198394 (Abcam plc, Cambridge, UK), human GAPDH: g9545 and beta-actin: a5441 (SigmaAldrich, St. Louis, MO, U.S.A). Secondary antibodies used were either against mouse or rabbit
(Sigma-Aldrich, St. Louis, MO, U.S.A) or goat (Santa Cruz Biotechnology, TX, U.S.A), as
appropriate. In some cases, LI-COR with infrared fluorescence, IRDye secondary antibodies and
LI-COR Odyssey CLx imaging system were also used to detect western blots without film or
chemiluminescent substrates. Western blots were analyzed and quantified using Odyssey CLx
imaging system, Image Studio version 51.
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RNA pulldown assay
RNA pulldown assay was performed with modifications of the protocol described by Wani et
al92. Cells were seeded in 10 cm plates. Cells were transfected with either 1nM synthetic
biotinylated scramble duplex (patent pending), or 1nM synthetic biotinylated miR-1207-3p
duplex (patent pending) using Lipofectamine RNAiMAX (Thermo Fisher Scientific Inc;
Wilmington, DE, U.S.A) for 24 hours, then lysed, according to the manufacturer’s instructions.
Beads were washed, blocked and prepared as described92. Target mRNA was captured and postcapture bead washing was performed. Next, target mRNA and control lysate RNA were purified
using Qiagen RNeasy kit (Cat no: 74104, Qiagen, Hilden, Germany) according to manufacturer’s
RNA clean-up protocol. The target mRNA and the control lysate were then quantified by
Nanodrop 1000 spectrophotometer. For the identification of direct targets of the mature miRNA,
using the synthetic biotinylated miR-1207-3p duplex, samples were analyzed by qRT-PCR to
examine the mRNA expression levels and enrichment of FNDC1 and c-MYC1.

Patients and Samples
For the human study at Moffitt Cancer Center, prostate cancer tissues were collected from 377
primary prostate cancers with macro-dissection (Table 3.1). Total RNA of tumor tissues was
extracted and RNA samples from the 377 patient cases were analyzed by qRT-PCR to examine
the mRNA expression levels of fibronectin. Ct-values were determined using the SDS ver2.3
software (Bio-Rad). Fibronectin expression was normalized with GAPDH expression within each
sample. Relative quantification of target gene expression was evaluated using the comparative
2ΔΔCtmethod. The following primers were used: Fibronectin-F: TCG AGG AGG AAA TTC CAA
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TG; Fibronectin-R: ACA CAC GTG CAC CTC ATC AT; GAPDH-F: ACC ACA GTC CAT GCC
ATC AC; GAPDH-R: TCC ACC ACC CTG TTG CTG TA.

To evaluate miR-1207-3p expression in clinical samples, we used tissue specimens from 404
patients (389 CM, and 15 moAA) with primary adenocarcinoma of the prostate from 1988 to 2003
at the Moffitt Cancer Center, Tampa, Florida, USA. After histopathologic confirmation, PCa
tissues were obtained from unstained slides with macro-dissection. Total RNA was extracted from
PCa tissues using superscript IV first-strand Synthesis system (Life technologies No. 18091200)
and quantified using UV spectrophotometer NanoDrop 2000 (Thermo Scientific, USA). The
cDNA templates were synthesized from RNA samples by SuperScript using random hexamers.
RNA samples from the 404 patient samples were analyzed by qRT-PCR to examine the expression
of miR-1207-3p.

Gene expression was determined using power SYBR Green Real time PCR Master Mix (Life
technologies No. 4367649) and 2.0 μl of cDNA template. qRT-PCR was performed on a ABI7900
machine using the following amplification conditions: 10 min at 95°C; followed by 45 cycles of
15 seconds at 95°C; 30 seconds at 55°C; and 30 seconds at 72°C. All assays were carried out in
triplicate to control for technical variance. Ct values were determined using the SDS ver2.3
software (Bio-Rad). miR 1207-3p expression was normalized with RNUB6_12 expressions within
each sample. Relative quantification of target gene expression was evaluated using the
comparative 2ΔΔCt.
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Institutional Review Board approvals were obtained for the study protocol at the University of
South Florida and the Moffitt Cancer Center, Tampa, Florida (Tables 3.1 & 3.2). Signed informed
consent was obtained from all study participants. Clinicopathological and demographic
information of the patients are summarized in Table 3.1 and Table 3.21,2,93.

In a separate study, we evaluated the expression profile of miR-1207-3p, FNDC1, FN1, AR and
c-MYC in histologically confirmed normal prostate tissue (n=24), benign prostate tissue (n=44)
and malignant prostate tissue (n=29) from prostatectomy or transrectal ultrasound-guided biopsies
in patients recruited at the University College Hospital, Ibadan, Nigeria. Analysis of miR-12073p, FNDC1, FN1, AR, and c-MYC expression in malignant prostate tissue with Gleason scores ≥8
versus Gleason scores <8 was performed. This study was performed following protocols approved
by both City University of New York Institutional Review Board and the University of Ibadan
Institutional Ethics Board. RNA extraction, cDNA synthesis and qRT-PCR were performed to
analyze mRNA expression of miR-1207-3p, FNDC1, FN1, AR and c-MYC.

Statistical Analysis
Differences in two and three clinical outcome groups were compared using the two-tailed
Student’s t-test and ANOVA test, respectively. For evaluating the association of miR-1207-3p
expression with PCa death and PCa recurrence in CM, a competing risk approach was applied.
miR-1207-3p expression was categorized to three groups: low (<3), median (3-6) and high (≥6)
based on the tertile cut-points. Factors associated with PCa death were evaluated using competingrisk regression 94. The cumulative incidence curves of PCa death were generated by the subgroups
of miR-1207-3p expression. For evaluating miR-1207-3p expression associated with PCa survival,
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PCa death was the primary interest and non-PCa death was treated as a competing risk. Survival
time was defined as the time from date of PCa diagnosis to date of death. For evaluating association
of miR-1207-3p expression with PCa recurrence, PCa recurrence was the primary interest and nonrecurrence death was treated as a competing risk. Time to event was defined as time from the date
of PCa diagnosis to PCa recurrence or non-recurrence death, whichever comes first. Data were
censored at the last follow-up date. The same approach was applied to evaluate the association of
miR-1207-3p expression with PCa recurrence. The candidate factors taken into consideration in
modeling included age at diagnosis, Gleason score, and tumor stage. PSA was excluded from the
models because the PSA values were missing in 150 CM. The level of significance was established
using a P value less than 0.052.

For functional experiments (proliferation, migration and apoptosis), results were collected from at
least three independent experiments. All results are presented as mean ± standard error of the mean
(SEM). Unless otherwise indicated, analysis of statistical significance of differences between
groups was performed using two-tailed Student’s t-test, and only values with P < 0.05 were
deemed significant. For comparison of variables, a student’s t test or analysis of variance
(ANOVA) test or Tukey post-hoc test were used for analysis of each set of continuous and
categorical data. Statistical differences in the relative miRNA expression profiles were determined
with one-way, two-way analysis of variance (ANOVA) and Tukey post-hoc test using the SPSS
Statistics software (http://www-01.ibm.com/software/analytics/spss/) on normalized data. P values
<0.05 were considered significant1,2.
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Chapter 3:
miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/FN1
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Introduction
PCa is a multi-factorial, complex disease, with the exact mechanisms for its development and
progression unclear10,12,95,96. Understanding the molecular mechanisms underlying the
development and progression of PCa is necessary. This will aid in the discovery of novel and
efficacious biomarkers with applications in early PCa detection and molecular therapeutic
targeting.

Genome-wide association studies (GWAS) have identified the 8q24 human chromosomal region
as one of the most important susceptibility loci for PCa13,48,51,86,97,98. Recent studies demonstrated
that PVT1, which is a 300kb long non-protein coding gene locus found at the 8q24 human
chromosomal region, is dysregulated in PCa51,97,99-101. The PVT1 gene locus encodes a cluster of
six microRNAs (miRNAs), including microRNA-1207-3p (miR-1207-3p)47,50,93. No known
biological functions for this intron-derived miR-1207-3p has been previously reported.

Aberrant miRNA expression and function has potential applications in cancers7,27,41. The objective
of this study was to determine the expression, function, and molecular mechanisms of action of
miR-1207-3p in PCa. Our study discovered a novel role of miR-1207-3p in the regulation of
critical cellular functions in PCa via direct targeting of fibronectin type III domain containing 1
(FNDC1), leading to loss of fibronectin (FN1) expression and subsequent loss of androgen
receptor (AR) expression. We also discovered that components of this novel molecular pathway,
FNDC1, FN1, and AR are overexpressed in metastatic PCa. This discovery of a novel miR-12073p-dependent regulatory mechanism in PCa reveals the possibility of clinical applications for miR1207-3p in PCa.
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Results

miR-1207-3p is significantly underexpressed in PCa cells
To investigate the expression profile, the functional role, and the molecular mechanisms of miR1207-3p in PCa, a panel of 8 prostate cell lines modeling different clinical characteristics of PCa
was used because of the widely known heterogeneity of PCa1. In detail, the panel included the
RWPE-1 (non-tumorigenic prostate epithelial cell line, Caucasian male (CM)), WPE1-NA22
(derived from RWPE-1, indolent, androgen-dependent, CM), MDA PCa 2b (aggressive, androgen
dependent, from a male of African ancestry (moAA)), PC-3 (aggressive, androgen-independent,
CM), E006AA (indolent, androgen-independent, moAA), E006AA-hT (derived from E006AA,
aggressive, androgen-independent, moAA), LNCaP (aggressive, androgen-dependent, CM) and
C4-2B (derived from LNCaP, aggressive, androgen-independent, CM)1 (Figure 3.1A). As shown
in figure 3.1B, miR-1207-3p expression is significantly underexpressed in all the human PCa cell
lines in comparison to non-tumorigenic prostate epithelial cells, RWPE-1. We observed nearly
50% less miR-1207-3p expression in androgen-dependent PCa cell lines (WPE1-NA22, MDA PCa
2b and LNCaP). Interestingly, the expression level of miR-1207-3p was even further decreased,
by approximately 80%, in androgen-independent cell lines (PC-3, E006AA, E006AA-hT and C42B). The data suggest that miR-1207-3p underexpression may be associated with the onset and
progression of PCa and could potentially be used as a new predictive biomarker for monitoring
the susceptibility of development of androgen-independent PCa.

To elucidate the role of miR-1207-3p expression in PCa cell function, commercially available
synthetic oligonucleotide mimic of miR-1207-3p (miR-1207-3p mimic), a synthetic
oligonucleotide inhibitor of miR-1207-3p (miR-1207-3p inhibitor), or a synthetic non-targeting
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negative control oligonucleotide (negative control) were transfected into the cells using
Lipofectamine® RNAiMAX. A dose-response experiment analyzed using qRT-PCR
demonstrated that the miR-1207-3p inhibitor suppresses endogenous expression of miR-1207-3p
while the miR-1207-3p mimic imitates endogenous miR-1207-3p expression; both in a dosedependent fashion (Figure 3.1C-E). A 50nM concentration of the miR-1207-3p inhibitor and the
miR-1207-3p mimic that showed maximal specific effect on miR-1207-3p expression was used to
determine the role of miR-1207-3p in regulating proliferation, migration and apoptosis in PCa
cells.

Figure 3.1: miR-1207-3p expression is lost in prostate cancer cells, and effect of an oligonucleotide
inhibitor and oligonucleotide mimic of miR-1207-3p on miR-1207-3p expression. (A) Characterization
of non-tumorigenic and tumorigenic prostate epithelial cells. List and characteristics of human prostate cell
lines used. CM, Caucasian Male; moAA, men of African Ancestry; AR, androgen receptor. (B) Three
separate qPCR experiments were performed. Each experiment was done in quadruplicates. The data showed
that miR-1207-3p expression was decreased in all the tumorigenic cell lines. (C) A dose-response test of
the effect of an oligonucleotide inhibitor of miR-1207-3p on miR-1207-3p expression was performed on
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RWPE-1 cells. As a control, RWPE-1 cells were treated with 50nM non-targeting negative control
oligonucleotide. (D & E) A dose-response test of the effect of an oligonucleotide inhibitor and an
oligonucleotide mimic of miR-1207-3p on miR-1207-3p expression was performed on WPE1-NA22 cells,
respectively. As a control, WPE1-NA22 cells were treated with 50nM non-targeting negative control
oligonucleotide. Dose-dependent inhibition and dose dependent overexpression of miR-1207-3p expression
by the oligonucleotide inhibitor and mimic of miR-1207-3p was observed. Results are presented as mean ±
standard error of the mean (SEM). Statistical differences were determined with one-way ANOVA. All the
criterions for significance was set at P<0.05. (Originally published in Experimental Cell Research1).

Overexpression of miR-1207-3p suppresses endogenous expression of fibronectin type III
domain containing 1 (FNDC1) and fibronectin (FN1) in PCa cells
To explore the molecular mechanisms through which miR-1207-3p exerts its inhibitory effects in
PCa, the potential molecular targets of miR-1207-3p were investigated. The molecular targets of
miR-1207-3p have never been studied in any system. To identify potential targets, two different
miRNA molecular target prediction algorithm tools, miRBase and miRDB, we used. Fibronectin
type III domain containing 1 (FNDC1) was identified as a putative molecular target of miR-12073p. FNDCI contains the conserved ‘Fibronectin type III domain’ of Fibronectin (FN1)52-55.
However, a functional role for FNDC1 in PCa has not been reported.

To initially determine if there is a relationship between FNDC1 expression, FN1 expression and
miR-1207-3p expression, we analyzed protein expression of FNDC1 in the prostate epithelial cell
lines described in figure 3.1A. We observed that FNDC1 protein expression was consistently
higher in all the PCa cell lines compared to the non-tumorigenic prostate cell line, RWPE-1 (Figure
3.2A). In repeated experiments, RWPE-1 had very low FNDC1 protein expression. Further,
overexpression of miR-1207-3p significantly inhibited the protein expression of FNDC1 by about
75% (Figure 3.2B).
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miR-1207-3p directly targets FNDC1
To confirm that FNDC1 is a direct molecular target of miR-1207-3p, we performed a dualluciferase reporter assay using the Luc-Pair™ Duo-Luciferase assay system to determine if miR1207-3p binds to the 3’ untranslated region (UTR) of the FNDC1 mRNA. Due to the heterogeneity
of PCa, we utilized widely used PCa cell lines that model various characteristics of PCa. Because
of the significantly low level of endogenous expression of miR-1207-3p in the PC-3 and MDA
PCa 2b PCa cell lines and their widespread use, we used them as cellular models for this assay.
PC-3 and MDA PCa 2b cells were co-transfected with both the plasmid containing the sequence
of the FNDC1 3’UTR and miR-1207-3p 50nM mimic. Cells were transfected with 3’UTR clones
of FNDC1 with a synthetic non-targeting oligonucleotide negative control as the control. We
observed a direct and specific interaction between exogenous miR-1207-3p and the FNDC1
3’UTR. Overexpression of miR-1207-3p led to the suppression of activity of the luciferase reporter
gene fused to the FNDC1 3’UTR by about 40% in PC-3 cells and about 60% in MDA PCa 2b cells
(Figure 3.2C) compared to the cells transfected with the non-targeting 50nM oligonucleotide
negative control.

As nearly 20% of miRNA mediated repression of target mRNAs occur without the canonical base
pairing to the seed sequence, but rather by imperfect binding to the center of miRNA sequence,
we further confirmed and validated that miR-1207-3p directly binds to FNDC1 by performing
RNA pulldown using a synthetic biotinylated miR-1207-3p duplex (Patent application publication
number, US20170121711 A1)92. This approach allows for the sensitive and specific detection of
miRNA-mRNA interactions92. MDA PCa 2b cells were transfected with either 1nM synthetic
biotinylated miR-1207-3p duplex or 1nM synthetic biotinylated scramble duplex as a control.
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RNA was subsequently pulled down with streptavidin coated magnetic beads. The RNA was then
analyzed for FNDC1 expression with qRT-PCR. We observed that compared to the RNA pulled
down by the synthetic biotinylated scramble duplex, the RNA pulled down by the synthetic
biotinylated miR-1207-3p duplex was significantly enriched for FNDC1 by approximately 2,000fold (Figure 3.2D). Therefore, FNDC1 is a direct molecular target of miR-1207-3p.

Figure 3.2: FNDC1 is a direct molecular target of miR-1207-3p. (A) Western blotting experiments were
performed. FNDC1 is overexpressed in PCa cell lines when compared to the non-tumorigenic prostate
epithelial cell line, RWPE-1. (B) Effect of overexpression of miR-1207-3p on FNDC1 in MDA PCa 2b
cells. (C) Luc-Pair™ Duo-Luciferase Assay was used to determine if miR-1207-3p binds to the 3’-UTR of
FNDC1. PC-3 and MDA PCa 2b cells were co-transfected with GeneCopoeia pEZX-MT06 miRNA
reporter empty vector or FNDC1 3’UTR-containing plasmid with a 50nM non-targeting negative control
or miR-1207-3p 50nM mimic for 24 hours. FLuc and RLuc activity were measured. Activity is normalized
to the negative control luciferase activity set to 1.0. Bars represent SD. *P<0.05. Data show that microRNA1207-3p directly targets the 3’UTR of FNDC1. (D) Biotinylated microRNA pulldown was performed for
the isolation of direct targets of a mature miRNA, using synthetic biotinylated miRNA duplexes.
Biotinylated scramble duplex and biotinylated microRNA-1207-3p duplex were transfected into MDA PCa
2b cells. Pull-down miRNA enrichments were assayed by qRT-PCR. Activity is normalized to the
biotinylated scramble duplex set to 1.0. Bars represent SD. *P<0.05. (Originally published in Experimental
Cell Research1).
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miR-1207-3p regulates FN1 via FNDC1
To examine the relationship between FN1 expression and miR-1207-3p, we analyzed mRNA and
protein expression of FN1 in the previously described cell lines (Figure 3.1). The data revealed
higher FN1 mRNA expression in all the PCa cell lines compared to non-tumorigenic RWPE-1 cell
line1 (Figure 3.3A). Interestingly, PCa cell lines from moAA (MDA PCa 2b, E006AA and
E006AA-hT) showed higher FN1 expression compared with cells from Caucasian men, suggesting
that FN1 may play a role in the racial disparity in PCa (Figure 3.3A). Additional validation by
western blotting confirmed increased FN1 protein expression in all the PCa cell lines compared to
the non-tumorigenic prostate epithelial cell line, RWPE-1 (Figure 3.3B). Further work was
performed, to assess the effect of inhibition or overexpression of miR-1207-3p on FN1 expression
in RWPE-1 cells. qRT-PCR analysis showed that overexpression of miR-1207-3p induced nearly
a 30% reduction of endogenous FN1 mRNA expression in RWPE-1 cells, while the inhibition of
miR-1207-3p led to nearly a 4-fold increase in endogenous FN1 mRNA expression (Figure 3.3C).
In addition, western blotting confirmed that overexpression of miR-1207-3p can significantly
inhibit the protein level of FN1, with up to a 40% decrease in FN1 protein expression in three
different PCa cell lines examined (Figure 3.3D). These findings demonstrate that FN1 is a
component of the molecular pathway regulated by miR-1207-3p in PCa.
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Figure 3.3: miR-1207-3p regulates FN1 expression. (A & B) Two separate qRT-PCR and western
blotting experiments were performed. Each qRT-PCR experiment was performed in quadruplicates. (C)
Effect of overexpression and inhibition of miR-1207-3p on fibronectin expression in RWPE-1 cells. qRTPCR experiments were performed in quadruplicates, and three separate times. Statistical differences for A
& C were determined with one-way ANOVA. All the criterions for significance was set at P<0.05. (D)
Effect of overexpression of miR-1207-3p on fibronectin expression in PC-3, E006AA cells, and E006AAhT cells. Western blot experiments were performed two separate times. (Originally published in
Experimental Cell Research1).

FNDC1 regulates proliferation, apoptosis, and migration of PCa cells
To determine if miR-1207-3p effects on PCa cellular function are due to its inhibitory effect on
FNDC1 expression, a FNDC1 small-interfering RNA (siRNA) was designed and used to determine
if the effects of loss of FNDC1 expression are identical to the effects of overexpression of miR1207-3p on PCa cellular function. A dose-response experiment using MDA PCa 2b cells was
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performed to determine the efficacy of our custom-designed FNDC1 siRNA in silencing FNDC1
protein expression (Figure 3.4A). FNDC1 siRNA downregulated the expression of FNDC1 protein
expression in MDA PCa 2b cells after 24-hour transfection best at 100pM concentration. This
100pM concentration was used to determine the effect of silencing FNDC1 expression on
apoptosis, proliferation and migration of PCa cells. To investigate whether FNDC1 regulates
apoptosis, an Annexin V analysis was performed. Transient transfection with FNDC1 siRNA
induced nearly 2-fold increase in apoptosis when compared to the scramble siRNA in C4-2B cells
(Figure 3.4B). The EdU proliferation assay revealed that proliferation of MDA PCa 2b cells was
inhibited by approximately 80% when compared to the scramble siRNA (Figure 3.4C). We
observed that migration, assessed via wound healing, of C4-2B cells was reduced significantly by
approximately 55% by transfection with FNDC1 siRNA as compared to the scramble siRNA
(Figure 3.4D). These results demonstrate that knockdown of FNDC1 via siRNA suppresses
cellular proliferation and migration while inducing apoptosis in a manner similar to that observed
for overexpression of miR-1207-3p, thus indicating that the cellular effects of miR-1207-3p are
due to its effect on FNDC1 expression.
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Figure 3.4: Effect of siRNA knockdown of FNDC1. (A) A dose response test of the effect of siRNA
knockdown of FNDC1 was performed on MDA-PCa 2b using western blotting. Cells were treated with a
non-targeting scramble siRNA and increasing concentrations of siRNA against FNDC1. Inhibition of
FNDC1 expression by the FNDC1 siRNA was dose-dependent. (B) Effect of 100pM siRNA against
FNDC1 on apoptosis of C4-2B cells via Annexin V staining. Inhibition of FNDC1 expression by the siRNA
increases apoptosis. (C) Effect of 100pM siRNA against FNDC1 on proliferation in MDA PCa 2b cells
using the Click-iT Edu proliferation assay (10X magnification). Inhibition of FNDC1 expression by the
siRNA inhibits proliferation. (D) Effect of 100pM siRNA against FNDC1 on C4-2b cells. Inhibition of
FNDC1 expression by the siRNA inhibits migration. (Originally published in Experimental Cell
Research1).
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FN1 regulates proliferation, apoptosis and migration of PCa cells
Next, a dose-response experiment was used to determine the efficacy of the custom-designed FN1
siRNA and appropriate concentrations for silencing FN1 protein expression (Figure 3.5A). We
observed that FN1 protein expression in PC-3 cells were reduced most effectively at a
concentration of 25pM, with an inhibition by approximately 80%. Therefore, this concentration
was chosen to determine if the knockdown of FN1 using siRNA affects cell proliferation,
migration and apoptosis in PCa cells in a manner similar to the effect of overexpression of miR1207-3p. FN1 protein expression decreased by up to 50% after transfection with FN1 siRNA
compared to the scramble negative control siRNA in three different PCa cell lines tested (Figure
3.5B).

A direct analysis of cell proliferation was performed using EdU labeling on MDA PCa 2b cells.
After 24 hours of transfection with either a scramble siRNA or 25pM FN1 siRNA, treatment with
FN1 siRNA significantly inhibited cell proliferation by about 70% (Figure 3.5C). An analysis of
the effects of FN1 siRNA on apoptosis using PC-3 cells was done by Annexin V analysis. We
observed about 50% increase in apoptosis after FN1 silencing (Figure 3.5D). To assess the effect
on cell migration, wound healing assays were performed using WPE1-NA22 cells. Inhibition of
FN1 expression using the 25pm siRNA significantly inhibited migration by about 80% in WPE1NA22 compared to the scramble (Figure 3.5E). These results indicate that FN1 regulates apoptosis,
proliferation and migration of PCa cells. The silencing of FN1 induced apoptosis, and inhibited
proliferation and migration in a manner similar to that of silencing of FNDC1, and overexpression
of miR-1207-3p.
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Figure 3.5: Effect of siRNA knockdown of fibronectin. (A) A dose response test of the effect of siRNA
knockdown of fibronectin was performed on PC-3 cells using western blotting. Cells were transfected with
10pM non-targeting scramble siRNA and increasing concentrations of siRNA against fibronectin.
Inhibition of fibronectin expression by our fibronectin siRNA was dose-dependent. (B) Effect of 25pM
siRNA against fibronectin in PC-3 cells, E006AA cells, and E006AA-hT cells, respectively. Western blot
experiments were performed three separate times. (C) Effect of a 25pM siRNA against fibronectin on
proliferation in MDA PCa 2b cells was assessed using the Click-iT Edu proliferation assay (10X
magnification). Inhibition of fibronectin expression by the fibronectin siRNA inhibits proliferation. (D)
Effect of 25pM siRNA against fibronectin on PC-3. Inhibition of fibronectin expression by the fibronectin
siRNA increases apoptosis. (E) Effect of 25pM siRNA against fibronectin on WPE1-NA22. Inhibition of
fibronectin expression by the fibronectin siRNA inhibits migration. (Originally published in Experimental
Cell Research1).
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miR-1207-3p regulates the androgen receptor via FNDC1/FN1
It is well established that aberrant AR expression and activity play a critical role in the development
and progression of PCa21,102-104. Thus, we wanted to investigate if miR-1207-3p regulates AR in
our novel pathway as this may play a determinant role in the progression from androgen-dependent
PCa to the incurable androgen-independent PCa (CRPC). We initially assessed AR protein
expression in the non-tumorigenic prostate epithelial cell line and PCa cell lines using western
blotting. We observed that AR protein expression, similar to FNDC1 and FN1 protein expression,
is overexpressed in the PCa cell lines compared to the non-tumorigenic prostate epithelial cell line,
RWPE-1. Moreover, AR protein expression, similar to FNDC1 and FN1 protein expression, is
very low in RWPE-1 (Figure 3.6A). In addition, FNDC1, FN1 and AR protein are overexpressed
in the androgen-independent C4-2B PCa cell line compared to the androgen-dependent LNCaP
PCa cell line (Figure 3.6B). Thus, the result shows that FNDC1 and FN1 expression positively
correlate to AR expression in PCa cell lines. It is interesting to note that AR expression is
negatively correlated with miR-1207-3p expression in PCa cell lines but is independent of the
aggressiveness of the PCa cell line (Figure 3.1B). To determine if miR-1207-3p regulation of
FNDC1/FN1 regulates AR expression, we examined the effect of silencing FNDC1 or FN1
expression on AR expression in PCa. FN1 siRNA was transfected into MDA PCa 2b cells and we
observed that compared to the scramble siRNA, FN1 siRNA inhibits AR expression (Figure 3.6C).
Therefore, AR expression is dependent on FN1 expression.

As we have already confirmed that miR-1207-3p directly targets the 3’UTR of FNDC1 leading to
loss of its expression, we wanted to determine if loss of FNDC1 expression leads to the loss of
FN1 and subsequent AR expression. Therefore, FNDC1 siRNA was transfected into MDA PCa

32

2b cells. To further clarify the role of miR-1207-3p in regulating FNDC1, and downstream
molecular mechanisms, we also compared the effect of overexpression of miR-1207-3p to the
effect of a negative control oligonucleotide. The western blot result clearly shows that the
overexpression of miR-1207-3p inhibits the protein expression of FNDC1 (>60%), FN1 (~40%),
and AR expression (~20%) (Figure 3.6D). The result positively correlates to that of the effect of
silencing FNDC1, with protein expression inhibition of >70% for FNDC1, >50% for FN1.
Remarkably, AR exhibits the most striking inhibition at nearly 85% (Figure 3.6D). Taken together,
the results indicate that miR-1207-3p binds to the 3’UTR of FNDC1 leading to loss of expression
of FNDC1, consequent loss of expression of FN1, and consequent loss of expression of AR. Thus,
we have demonstrated, for the first time a miR-1207-3p/FNDC1/FN1/AR novel regulatory
pathway.

Figure 3.6: miR-1207-3p/FNDC1/FN1/AR is a regulatory pathway in prostate cancer. (A) AR is
overexpressed in PCa cell lines when compared to the non-tumorigenic prostate epithelial cell line, RWPE1. (B) Relative protein expression of FNDC1, Fibronectin, and AR expression in LNCaP and C4-2b cells,
respectively. (C) Effect of silencing fibronectin expression on AR expression in MDA PCa 2b cells. (D)
Effect of overexpression of miR-1207-3p and silencing of FNDC1 on FNDC1, FN1 and AR expression in
MDA PCa 2b cells. Western blotting experiments were performed three separate times. (Originally
published in Experimental Cell Research1).
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FNDC1, FN1, and AR expression are positively correlated in human prostate cancers and
upregulation is associated with aggressive disease
In view of this novel discovery of FNDC1, FN1 and AR as downstream molecular mechanisms of
action of miR-1207-3p in PCa, we wanted to determine if they are relevant to clinically significant
disease in human PCa patients. We independently analyzed data from three separate studies:
Moffitt Cancer Center-based study, and analysis of two publicly available gene expression datasets
in the Oncomine database (www.oncomine.org).

In an independent study based at the Moffitt Cancer Center, we discovered that FN1 expression in
PCa cases that resulted in overall death (3.01±1.92 versus 2.18±1.67, P=0.001) or PCa-specific
death (2.88±2.11 versus 2.18±1.68, P=0.001) is significantly higher than PCa patients that
remained alive. These results are based on analysis of FN1 expression in 377 cases (Table 3.1).
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Table 3.1. Fibronectin expression in prostate cancer tissues of 377 patients. List and characteristics of
human prostate cancer samples. Variables: number, mean; SD, standard deviation; P-value. (Originally
published in Experimental Cell Research1).

Further, we independently investigated two additional publicly available gene expression datasets
in the Oncomine database (www.oncomine.org) for expression of FNDC1, FN1, and AR. Analysis
of the study conducted by Lapointe et al 96 revealed similar levels of upregulation of all three genes
in localized prostate cancers as compared to benign prostate tissues (FNDC1: 1.17 fold, p=0.002;
FN1: 1.15 fold, p=0.005; AR: 1.12 fold, p=0.117) (Figure 3.7A). Furthermore, metastatic prostatic
cancers showed an even higher level of upregulation as compared to the localized prostate cancers
(FNDC1: 1.80 fold, p=5.96e-4; FN1: 2.65 fold, p=0.063; AR: 2.87 fold, p=0.001) (Figure 3.7B).
Similarly, in the dataset from the study by Grasso et al. 105, metastatic prostate cancers showed a
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significant upregulation of all three genes when compared to localized primary prostate cancers
(FNDC1: 3.87 fold, p=6.49e-9; FN1: 3.36 fold, p=1.01e-7; AR: 3.34 fold, p=6.27e-4) (Figure 3.7C).
Together, these findings indicate a positive correlation between FNDC1, FN1, and AR expression
in prostate cancers similar to that seen in prostate cancer cell lines, and their upregulation in
metastatic prostate cancers supports a role for FNDC1, FN1, and AR in aggressive prostate
cancers.

Figure 3.7: FNDC1, FN1, and AR expression is correlated in prostate cancers and upregulation is
associated with aggressive disease. (A) Expression of FNDC1, FN1 and AR genes in benign prostate
tissues compared to localized prostate cancer. (B) Expression of FNDC1, FN1 and AR genes in localized
prostate cancer compared to metastatic prostate cancer. (C) Expression of FNDC1, FN1 and AR genes in
localized primary prostate cancer compared to metastatic prostate cancer. Results demonstrate upregulation
of FNDC1, fibronectin and AR in aggressive disease. (Originally published in Experimental Cell
Research1).

miR-1207-3p is differentially expressed in PCa in men of African ancestry compared to
Caucasian men
For reasons still unclear, men of African ancestry (moAA) have the highest incidence of PCa
globally 47,81-83. MoAA have approximately two-thirds higher incidence and two times the
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increased mortality rate compared to Caucasian men (CM) 47,83,85,106. Additionally, moAA are
more frequently diagnosed with worse clinicopathological features (PSA levels, Gleason grades,
advanced tumor stage, etc.) than CM 81,83,88,107.

Consequently, we investigated the clinical significance of miR-1207-3p in PCa and to determine
if it contributes to the disproportionate aggressiveness of PCa in moAA. We observed that miR1207-3p expression was significantly less in PCa tissues of moAA in comparison to the PCa tissues
of CM (3.00±2.65 versus 5.36±3.76, P = 0.016) (Table 3.2)2. This suggests that miR-1207-3p may
play a role in explaining the disproportionately increased aggressiveness of PCa in moAA2.
Variables
Race

N

Mean ±SD

moAA

15

3.00±2.65

CM

389

5.36±3.76

P

0.016

Table 3.2: miR-1207-3p is differentially expressed between moAA and CM. Description and
characteristics of human prostate cancer samples from 404 patients. N, Number; Avg, Average; SD,
Standard Deviation; P, P-value. (Originally published in Translational Oncology2).

miR-1207-3p regulates migration, apoptosis and proliferation of PCa cells
To investigate the function of miR-1207-3p in prostate epithelial cells, we first evaluated its role
in cell migration. Wound healing assays were performed using RWPE-1 (Figure 3.8A), WPE1NA22 (Figure 3.8B) and PC-3 cells (Figure 3.8C). As shown in figure 3.8A-C, inhibition of miR1207-3p expression with the miR-1207-3p inhibitor led to a four-fold increase in the migratory
capacity of all three prostate epithelial cell lines. Conversely, overexpression of miR-1207-3p
using the mimic of miR-1207-3p inhibited migration by 50% in both PCa cell lines, WPE1-NA22
(Figure 3.8B) and PC-3 (Figure 3.8C), thus showing that miR-1207-3p suppresses PCa cell
migration.
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To investigate whether miR-1207-3p affects cell apoptosis, we performed Annexin V staining
using flow cytometry on RWPE-1, MDA PCa 2b and C4-2B cells. We observed that for the normal
prostate epithelial cell line, RWPE-1, the overexpression of miR-1207-3p mimic only slightly
increased apoptotic activity. However, the miR-1207-3p inhibitor decreased apoptosis by nearly
2-fold (Figure 3.8D). miR-1207-3p inhibitor decreased apoptosis, but overexpression of the miR1207-3p mimic resulted in increased apoptotic activity when compared to the negative control in
MDA PCa 2b cells (Figure 3.8E). Similarly, the overexpression of miR-1207-3p mimic resulted
in increased apoptosis in C4-2B cells, by nearly 2-fold, when compared to the negative control
(Figure 3.8F). These results indicate that miR-1207-3p induces apoptosis in PCa cells.

We next investigated whether miR-1207-3p regulates proliferation, by performing Click-iT EdU
Alexa Flour 488 imaging assay. This sensitive method measures a cell’s ability to proliferate by
assessing the cells in S-phase. As shown in figure 3.8G-I, the effect of miR-1207-3p mimic and
the miR-1207-3p inhibitor were compared to the negative control in RWPE-1, MDA PCa 2b and
WPE1-NA22 cells. For the normal prostate epithelial cell line, RWPE-1, we observed that
overexpression of miR-1207-3p reduced EdU positive cells by approximately 30% compared to
the negative control, while the inhibition of miR-1207-3p led to a nearly 2.5-fold increase in
proliferation (Figure 3.8G). For MDA PCa 2b and WPE1-NA22 PCa cell lines, we observed that
EdU positive cells were reduced by nearly 70% by the overexpression of miR-1207-3p compared
to the negative control, while the inhibition of miR-1207-3p led to an approximate 40% increase
in proliferation (Figure 3.8H & I). The diminished percentage of cells in S-phase caused by the
overexpression of miR-1207-3p indicates that cells with overexpression of miR-1207-3p suspend
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the cell cycle as they are unsuccessful to progress through the S-phase. The results demonstrate
that increased expression of miR-1207-3p significantly inhibits cellular proliferation in PCa.

Figure 3.8: Loss of miR-1207-3p expression promotes migration, proliferation and inhibits apoptosis.
Transfection of a synthetic oligonucleotide mimic or inhibitor of miR-1207-3p was performed. (A) Effect
of inhibition of miR-1207-3p expression on migration of RWPE-1 cells. (B & C) Effect of overexpression
of miR-1207-3p and inhibition of miR-1207-3p on migration of WPE1-NA22 and PC-3 cells, respectively.
Data indicate that loss of miR-1207-3p promotes migration. (D) Effect of overexpression of miR-1207-3p
and inhibition of miR-1207-3p expression on apoptosis of RWPE-1 and MDA PCa 2b was assessed using
Annexin V staining, respectively (D & E). Effect of overexpression of miR-1207-3p on apoptosis of C4-2b
cells assessed using Annexin V staining. Data indicate that overexpression of miR-1207-3p expression
induces apoptosis (F). Effect of overexpression of miR-1207-3p and inhibition of miR-1207-3p expression
on proliferation of RWPE-1, MDA PCa 2b and WPE1-NA22 cells assessed using the Click-iT EdU
proliferation assay (10X magnification) (G-I). Results indicate that loss of miR-1207-3p increases
proliferation. Data is presented as mean + standard error of the mean (SEM). Statistical differences were
determined with two-way ANOVA for B-C, G-I. All the criterions for significance was set at P<0.05.
(Originally published in Experimental Cell Research1).
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Discussion
Prostate cancer (PCa) is the most frequently diagnosed solid organ cancer in males in the
developed world

108

. Despite the high prevalence, the molecular mechanisms underlying its

development and progression remain largely unclear. Increasing evidence has demonstrated that
many miRNAs are aberrantly expressed in cancers, suggesting that variations in miRNA
expression are common events in tumorigenesis34,41,43. These small non-coding RNAs are
attractive for clinical applications for many reasons. One compelling reason is that miRNAs direct
targeting of many mRNAs that are translated to proteins explains miRNAs differential expression
between non-cancer and cancer cells. Understanding the regulatory pathways controlled by
miRNAs is crucial as they can have significant impact on the regulation of various genes. The
current study provides novel insight into the underlying molecular mechanisms for a potential
tumor suppressive role for miR-1207-3p in PCa. The data suggest that it may be possible to exploit
miR-1207-3p as a definitive therapeutic strategy in PCa.

miRNA-1207-3p is encoded at the non-protein coding gene locus PVT1 on the 8q24 human
chromosomal region, an established PCa susceptibility locus50,51. However, miRNA-1207-3p is
not associated with any annotated PVT1 exons and no known functions have previously been
described for miR-1207-3p. Thus, the function of miR-1207-3p may be different from that of
PVT1 or any of its annotated exons. As the expression of miR-1207-3p in PCa has not previously
been reported, our study is the first to demonstrate that miR-1207-3p regulates molecular
mechanisms and central cellular functions associated with PCa development and progression. An
important discovery is that miR-1207-3p is significantly underexpressed in human PCa cell lines
as compared to normal prostate epithelial cells (by more than two-fold). Furthermore, based on the
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observation that miR-1207-3p expression was further reduced in PCa cell lines derived from
castration-resistant PCa (CRPC) versus castration-sensitive PCa, this study suggests that loss of
miR-1207-3p may potentially be an early PCa biomarker of progression to CRPC.

It is well known that being of African ancestry is a non-modifiable risk factor for PCa.82,83 These
men are more than twice as likely to be diagnosed with PCa and more likely to have aggressive
subtypes which increases their risk of mortality.83,109 Although the importance of miRNAs in PCa
in moAA is still unclear, our results show that miR-1207-3p expression is particularly low in PCa
cell lines derived from moAA (MDA PCa 2b, E006AA and E006AA-hT). More importantly,
results from human studies suggests that miR-1207-3p may contribute to the disproportionate
aggressiveness of PCa in moAA. In this regard, miR-1207-3p is differentially expressed in primary
tumors of moAA tissues compared to primary tumors of CM. To our knowledge, this is the first
report of a microRNA that directly correlates with aggressive PCa, yet shows divergent expression
between CM and moAA2. These data suggest that it may be possible to predict clinical behavior
of PCa based upon miRNA-1207-3p expression in primary PCa. While the overall sample size of
the present study is relatively large, a limitation is the small sample size of the moAA sub-group.
Although challenging, due to issues related to recruitment, a larger study enriched with a
substantial proportion of moAA is warranted. In addition, the present study did not examine miR1207-3p expression in non-tumor versus tumor tissues. Therefore, the current data do not provide
information regarding whether miR-1207-3p is differentially expressed in normal prostate versus
PCa tissue2. Further studies evaluating the role of miR-1207-3p in PCa racial disparity are
required.
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Since the seven tumorigenic PCa cell lines studied showed consistent and significant
underexpression of miR-1207-3p compared to the non-tumorigenic prostate epithelial cell line
RWPE-1, we investigated the role of miR-1207-3p in regulating key cellular processes
(proliferation, apoptosis, and migration) that are dysregulated during the development and
progression of PCa. Whereas inhibition of miR-1207-3p expression leads to inhibition of apoptosis
and increases in cellular proliferation of PCa cells, overexpression of miR-1207-3p significantly
induced apoptosis and inhibited proliferation of PCa cells. Strikingly, inhibition of miR-1207-3p
led to an approximately four-fold increase in the migratory capacity of both non-tumorigenic and
tumorigenic prostate epithelial cells. These data demonstrate that miR-1207-3p regulates key
cellular processes dysregulated in the development and progression of PCa110. Consequently, it is
possible that miR-1207-3p could be applied to modulate these processes for therapeutic effects in
PCa. Therefore, strategies to increase expression of miR-1207-3p in prostate epithelial cells
deserve thorough investigation.

The effect of miR-1207-3p on cellular migration is especially remarkable. Two miRNA molecular
target algorithm tools, miRBase and miRDB, independently identify FNDC1 as a putative
molecular target of miR-1207-3p. As demonstrated, overexpression of miR-1207-3p inhibited
expression of FNDC1 in multiple PCa cell lines. In addition, luciferase reporter assay and RNA
pulldown assay confirmed that miR-1207-3p directly binds to FNDC1. Thus, we are first to
demonstrate FNDC1 as a direct molecular target of miR-1207-3p. FNDC1 contains a major
component of the structural domain of FN152,54,55,57,59. FN1 has been implicated in many cancers
and known to be a major regulator of migration of cancer cells

61-64,111

. Overexpression of miR-

1207-3p downregulates FN1, and specific silencing of FNDC1also downregulates FN1. Thus,
miR-1207-3p effects in PCa are due to binding to and loss of FNDC1, and subsequent loss of FN1.
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The biological function of FNDC1 has not been well studied. To our knowledge, this study is the
first to demonstrate microRNA regulation of FNDC1. So far, only two miRNAs have been shown
to directly target a member of the FN1 family in PCa, miRs-143 and-145 which are both
downregulated in PCa cell lines and tissues65,66. However, these studies did not reach a consensus
on their effects on FN134,65,67. Nevertheless, FN1 is upregulated in PCa as we observed from three
independently analyzed human studies64,112. By identifying miR-1207-3p as a regulator of FN1,
and its subsequent role in the regulation of proliferation, apoptosis, and migration, FNDC1 is
shown to have a clear and prominent role in PCa.

We have also demonstrated that miR-1207-3p regulates AR activity via FNDC1 and FN1. AR
signaling is not only crucial for normal prostate growth and development but also for the onset and
progression of prostate carcinogenesis104. Although AR signaling has been studied for decades,
the molecular mechanisms behind its dysfunction remain unclear21,104,113. Undoubtedly, AR
dysfunction precedes the progression CRPC21,103. We demonstrated that AR protein expression, in
positive correlation with FN1 and FNDC1 protein expression, is significantly more elevated in the
CRPC cellular model, C4-2B, in comparison to its castration-responsive counterpart, LNCaP. In
summary, we have demonstrated the molecular effects of miR-1207-3p: loss of FNDC1 expression
and consequent loss of FN1 expression lead to loss of AR expression. Thus, this is the first
description of a novel miR-1207-3p/FNDC1/FN1/AR regulatory pathway in PCa (Figure 3.9) 1,93.
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Figure 3.9: A novel miR-1207-3p/FNDC1/FN1/AR regulatory pathway in prostate cancer.
MicroRNA-1207-3p inhibits proliferation and migration and induces apoptosis of prostate cancer cells by
the direct molecular targeting of the 3’UTR of FNDC1. miR-1207-3p induced loss of FNDC1expression
leads to the sequential loss of FN1 and AR expression. (Originally published in RNA & Disease93).

The clinical relevance of this novel regulatory pathway was investigated in several independently
analyzed human prostate studies: Moffitt Cancer Center-based study, and analysis of two publicly
available gene expression datasets in the Oncomine database (www.oncomine.org). To our
knowledge, these are the first concurrent analyses of FNDC1, FN1, and AR in human PCa. Our
Moffit Cancer Center-based study strongly showed that FN1 overexpression positively correlated
with overall death and PCa-specific death in PCa. To our knowledge, this is the first description
of FN1 as a prognostic biomarker in human clinical PCa. Importantly, analysis of the two publicly
available gene expression datasets in the Oncomine database very strongly showed concurrent
overexpression of FNDC1, FN1, and AR in metastatic PCa in comparison to primary tumors in
both datasets. This is very clear evidence of an important role of this novel FNDC1/FN1/AR
molecular pathway regulated by miR-1207-3p in the most clinically significant PCa, metastatic
PCa. This underscores the importance of further studying miR-1207-3p for potential therapeutic
applications especially for metastatic PCa.
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Chapter 4:
c-MYC is regulated and therapeutically targetable via the miR-1207-3p/FNDC1/FN1/AR
pathway in castration resistant prostate cancer
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Introduction

Although PCa is second leading cause of cancer-related death for men in the US, men with PCa
do not die from localized prostate cancer9,12,11,25,103,105. Consequently, the major scientific
challenge lies in understanding the molecular mechanisms by which prostate cancer progresses
from the castration-responsive subtype to the lethal castration-resistant PCa (CRPC)17,25,103.

In the US, the average 5-year survival rate for localized PCa is 100%, but for CRPC it is less than
30%17,18,114. CRPC is resistant to androgen deprivation therapies (ADT), and is currently
incurable17,18,25,103. Despite CRPCs resistance to ADT, it is now well established that a central
mechanism driving CRPC progression is sustained androgen receptor (AR) signaling despite
castration levels of testosterone which can be attributed to variable combinations of AR specific
gene-amplification, mutations, increased AR sensitivity, and AR gene rearrangement promoting
synthesis of constitutively-active truncated AR splice variants32,115-118. Given the failure of ADT
to completely abrogate AR-mediated functions in CRPC patients, there remains a significant
demand for novel, effective and safe therapeutic strategies for CRPC115,118. Furthermore, the
current tool for screening for PCa, prostate specific antigen (PSA), is highly controversial as it is
not PCa-specific and has a high false positive rate14,15. Consequently, new biomarkers are urgently
needed for the early detection of PCa, and it is crucial that these novel biomarkers are sensitive
enough to discriminate between indolent PCa and CRPC.

Because miRNAs are found to be dysregulated in many cancers, they have the potential to be used
as potent tools to support the diagnosis and early detection of cancers7,27,43. Of note, miR-1207-3p
is located downstream of the well-established proto-oncogene c-MYC on the 8q24 human
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chromosomal region (Figure 4.1)72,97. c-MYC overexpression at the RNA and protein levels has
subsequently been linked to a wide variety of human cancers72,75,76. Additionally, c-MYC is
commonly found to be amplified in up to 72% of CRPCs72,75,76. Furthermore, significant
amplification of c-MYC has been a consequence of antiandrogen treatment, and c-MYC is
downstream of AR in some PCa75,76. Also, miRNAs have been implicated in the regulation of cMYC79,80,119. Nonetheless, the mechanisms regulating c-MYC remain unclear in PCa.

Figure 4.1: c-MYC has been linked to prostate cancer aggressiveness. The chromosomal region 8q24
is associated with aggressive PCa. miR-1207-3p is encoded at the PVT1 gene locus, which is located
downstream of c-MYC.

This study investigated if c-MYC is regulated by the novel miR-1207-3p/FNDC1/FN1/AR
pathway in CRPC. We also describe for the first time miR-1207-3p’s ability to potentially improve
risk stratification in human clinical PCa. Additionally, using in vitro CRPC cell models, the
efficacy of NB1207 and NB5 was compared with second generation anti-androgen drugs to
evaluate their therapeutic potential in CRPC treatment.
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Results

Underexpression of miR-1207-3p and the overexpression of FNDC1, FN1, AR and c-MYC
are significantly associated with aggressive prostate cancer
We assessed the expression profile of miRNA-1207-3p, FNDC1, FN1, AR and c-MYC in
histologically confirmed normal prostate (n=24), benign prostatic hyperplasia tissue (n=44) and
malignant prostate tumor tissue (n=29) from prostatectomy or transrectal ultrasound-guided
biopsies in patients recruited at the University College Hospital, Ibadan, Nigeria, following an
Institutional Ethics Board approved protocol. Analysis revealed that miR-1207-3p is significantly
underexpressed in prostate tumor tissues (0.10±0.02, 95% CI [0.05, 0.149], P=0.000) in
comparison to normal prostate tissue (1.02±0.17, 95% CI [0.67, 1.365], P=0.000) (Figure 4.2).
Furthermore, there was significant differential miR-1207-3p expression in benign prostatic
hyperplasia tissues (0.743±.15, 95% CI [.43, 1.05] P=0.004) in comparison to prostate tumor
tissues (0.10±0.02, 95% CI [0.05, 0.149], P=0.004) (Figure 4.2). This is the first description of
miR-1207-3p differential expression in human clinical PCa.

Conversely, FNDC1 was significantly overexpressed in prostate tumor tissues (21.93±7.60, 95%
CI [6.30, 37.54], p=0.006) in comparison to normal prostate tissues (1.62±0.41, 95% CI [0.756,
2.48], p=0.006) (Figure 4.3A). Additionally, we discovered that FNDC1 was significantly
overexpressed in prostate tumor tissues (21.93±7.60, 95% CI [6.30, 37.54], p=0.001) in
comparison to benign prostatic hyperplasia tissues (1.22±.17, 95% CI [.86, 1.57] P=0.001) (Figure
4.3A). We observed that similar positive correlation with advanced disease held true for FN1
(tumor: 13.71 ± 3.31, 95% CI [6.93, 20.50], P=0.000; normal: 1.11 ± 0.22, 95% CI [0.66, 1.57],
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P=0.000), (tumor: 13.71 ± 3.31, 95% CI [6.93, 20.50], P=0.000; benign prostatic hyperplasia
tissues: 1.12 ± 0.20, 95% CI [0.72, 1.53], P=0.000), AR (tumor: 20.33 ± 6.20, 95% CI [7.54,
33.13], P=0.001; normal: 1.06 ± 0.22, 95% CI [0.61, 1.52], P=0.001), (tumor: 20.33 ± 6.20, 95%
CI [7.54, 33.13], P=0.000; benign: 1.69 ± 0.23, 95% CI [1.21, 2.16], P=0.000) (Figure 4.3A-C),
and c-MYC (tumor: 34.76 ± 8.11, 95% CI [18.09, 51.43], p=0.000; normal: 1.99 ± 0.34, 95% CI
[1.27, 2.70]), (tumor: 34.76 ± 8.11, 95% CI [18.09, 51.43], p=0.000; benign: 1.01 ± 0.21, 95% CI
[0.59, 1.43]), p=0.000) (Figure 4.4). The significantly increased mean expression for FNDC1,
FN1, AR and c-MYC in prostate tumor tissues in comparison to normal prostate tissues
demonstrate that their overexpression is associated with increased risk of cancer progression. Of
note, this is the first description of miR-1207-3p serving as a candidate biomarker which can
differentiate between benign prostatic hyperplasia and aggressive PCa.
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Figure 4.2: Underexpression of miR-1207-3p is significantly associated with aggressive PCa. miR1207-3p, in histologically confirmed normal prostate (n=21), benign prostatic hyperplasia (n=41) and
malignant prostate tissue (n=26) from prostatectomy or transrectal ultrasound-guided biopsies in patients
recruited at the University College Hospital, Ibadan, Nigeria. Tissues were collected in compliance with
Institutional Ethics Board approved protocols. All data were analyzed by the one-way ANOVA test &
Tukey post-hoc test. P < 0.05 were considered significant.
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Figure 4.3. Overexpression of FNDC1, FN1, and AR are significantly associated with aggressive PCa.
(A-C) FNDC1, FN1, and AR in histologically confirmed normal prostate, benign prostatic hyperplasia, and
malignant prostate tissue from prostatectomy or transrectal ultrasound-guided biopsies in patients recruited
at the University College Hospital, Ibadan, Nigeria. Tissues were collected in compliance with Institutional
Ethics Board approved protocols. All data were analyzed by the one-way ANOVA test & Tukey post-hoc
test. P < 0.05 were considered significant.
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Figure 4.4: Overexpression of c-MYC is significantly associated with aggressive PCa. c-MYC, in
histologically confirmed normal prostate (n=21), benign prostatic hyperplasia (n=43) and malignant
prostate tissue (n=27) from prostatectomy or transrectal ultrasound-guided biopsies in patients recruited at
the University College Hospital, Ibadan, Nigeria. Tissues were collected in compliance with Institutional
Ethics Board approved protocols. All data were analyzed by the one-way ANOVA test & Tukey post-hoc
test. P < 0.05 were considered significant.

miR-1207-3p negatively correlates with c-MYC in prostate tumors with Gleason score ≥8.
Next, we wanted to access miR-1207-3p’s ability to improve risk stratification in human clinical
PCa. We analyzed miR-1207-3p in histologically confirmed malignant prostate tumor tissues
(n=23). We observed that miR-1207-3p was underexpressed by nearly 3-fold in patients with a
Gleason score ≥8 (n=10) versus those with a Gleason score <8 (n=13) (Figure 4.5A). In contrast,
we observed that c-MYC was overexpressed by nearly 5-fold in patients with a Gleason score ≥8
(n=13) versus those with a Gleason score <8 (n=14) (Figure 4.5B). Therefore, miR-1207-3p
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negatively correlates with c-MYC in tumors with Gleason score ≥8. This is the first description of
miR-1207-3p’s potential role in risk stratification in human clinical PCa.

Figure 4.5: miR-1207-3p negatively correlates with c-MYC in tumors with Gleason score ≥8.
Expression profile of miR-1207-3p and c-MYC in histologically confirmed malignant prostate tissue
(n=27) from prostatectomy or transrectal ultrasound-guided biopsies in patients recruited at the University
College Hospital, Ibadan, Nigeria. Tissues were collected in compliance with Institutional Ethics Board
approved protocols. All data were analyzed by the one-way ANOVA test & Tukey post-hoc test. P < 0.05
were considered significant.

c-MYC is downstream of the novel miR-1207-3p/FNDC1/FN1/AR pathway
In light of our results demonstrating an inverse correlation between miR-1207-3p and c-MYC, we
next investigated if c-MYC may possibly be a direct molecular target of miR-1207-3p. An RNA
pulldown assay was performed using our custom-designed biotinylated miR-1207-3p duplex
(NB1207) and our custom-designed biotinylated scramble oligonucleotide duplex (NB1), as a
control. This technique allows for the definitive detection of miRNA-mRNA interactions1,93. C454

2B cells were transfected with either NB1207 or NB1, as a control. RNA pulled down was then
analyzed for c-MYC expression with qRT-PCR. We observed that compared to the RNA pulled
down by our custom-designed biotinylated scramble oligonucleotide sequence, the RNA pulled
down by our custom-designed biotinylated miR-1207-3p duplex was not enriched for c-MYC
expression (Figure 4.6A). Therefore, c-MYC is not a direct molecular target of miR-1207-3p.

Although c-MYC is not a direct molecular target of miR-1207-3p, we observed an inverse
association with miR-1207-3p and positive association with FNDC1, FN1 and AR in human PCa.
Given that c-MYC has been reported to be downstream of AR in some PCa, we wanted to
determine if c-MYC is downstream of the novel miR-1207-3p/FNDC1/FN1/AR pathway.
Consequently, we assessed the effect of siRNAs against FNDC1, FN1 and AR on c-MYC mRNA
and protein expression in the E006AA and the E006AA-hT PCa cell lines. Compared to the control
scramble siRNA, siRNAs against FNDC1, FN1 and AR revealed significant suppression of cMYC expression by >90% in the E006AA PCa cell line and >75% in the E006AA-hT PCa cell
line, validating that c-MYC is downstream of the novel miR-1207-3p/FNDC1/FN1/AR pathway
and that miR-1207-3p regulates c-MYC expression via the miR-1207-3p/FNDC1/FN1/AR
pathway (Figure 4.6B-G).
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Figure 4.6: c-MYC is not a direct molecular target of miR-1207-3p but is regulated by the miR-12073p/FNDC1/FN1/AR pathway. (A) Biotinylated miRNA pulldown was performed for the isolation of
direct targets of a mature miRNA, using synthetic biotinylated miRNA duplexes. NB1 and NB1207 were
transfected into C4-2B cells. Pull-down miRNA enrichments were assayed by RT-qPCR. (B-D) Effect of
siRNAs against FNDC1, FN1 and AR on c-MYC mRNA expression in the indolent PCa cell line, E006AA,
respectively. (E-G) Effect of siRNAs against FNDC1, FN1 and AR on c-MYC mRNA expression in the
castration-resistant PCa cell line, E006AA-hT, respectively. Results are presented as mean + SEM. *P<0.05
compared to the control.
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A novel synthetic analog of miR-1207-3p, NB1207, significantly inhibits c-MYC expression
in CRPC cells.
To further determine if miR-1207-3p regulates c-MYC, we assessed the effect of overexpression
of miR-1207-3p on c-MYC protein expression, using NB1207, our synthetic analog of miR-12073p. Using our panel of PCa cell lines, we discovered that c-MYC expression is higher in aggressive
CRPC cell lines compared to non-aggressive CRPC and androgen-dependent PCa cell lines
(Figure 4.7A). Of note, our results reveal that c-MYC expression is higher in the aggressive C42B and E006AA-hT PCa cell lines when compared to their indolent counterparts, LNCaP and
E006AA PCa cell lines, respectively (Figure 4.7A). This suggests that c-MYC is associated with
aggressive PCa.

To determine if NB1207 inhibits c-MYC expression, we explored the effect of overexpression of
NB1207 on c-MYC mRNA and protein expression. We observed that NB1207 significantly
inhibited c-MYC mRNA expression when compared with a control synthetic sequence in the
CRPC cell lines, PC-3 (~60%), E006AA-hT (~35%) and C4-2B (~50%) (Figure 4.7B). Moreover,
we observed that NB1207 significantly inhibited c-MYC protein expression when compared with
the control synthetic sequence in the CRPC cell lines PC-3, E006AA-hT and C4-2B either as
effectively or more effectively than the commercially available miR-1207-3p mimic (SigmaAldrich MISSION® microRNA Mimic) (Figure 4.7C). We observed that in the CRPC cell lines,
PC-3, E006AA-hT and C4-2B, miR-1207-3p regulates c-MYC expression via the miR-12073p/FNDC1/FN1/AR pathway (Figure 4.7D-F). Compared to the controls (no transfection, control
synthetic sequence, and scramble siRNA), c-MYC protein expression is inhibited in the CRPC cell
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lines C4-2B (>75%), PC-3 (>80%) and E006AA-hT (>40%) by overexpression of miR-1207-3p,
and loss of expression of FNDC1, FN1, and AR (Figure 4.7D-F).

Figure 4.7: A novel miR-1207-3p/FNDC1/FN1/AR/c-MYC pathway in CRPC in which NB1207
significantly inhibits c-MYC expression in CRPC cells. (A) Relative protein expression of c-MYC in
PCa cell lines. (B) Effect of transfection of NB1207 on c-MYC mRNA expression in CRPC cell lines. (C)
Comparison of effect of transfection NB1 or NB1207 on c-MYC protein expression compared to negative
control or commercial miR-1207-3p mimic in CRPC cell lines. (D-F) Effect of novel miR-12073p/FNDC1/FN1/AR/c-MYC pathway on c-MYC protein expression in CRPC cell lines. All results are
presented as mean + standard error of the mean (SEM). *P<0.05 compared to the control.
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NB1207 significantly inhibits migration, inhibits proliferation and induces apoptosis in
CRPC cells.
We next compared the effects of NB1207 to that of a commercially available miR-1207-3p mimic
and scramble control on PCa cell proliferation, migration and apoptosis. We investigated whether
NB1207 regulates migration similar to the miR-1207-3p mimic. Wound healing assays were
performed to assess effect on migration of the E006AA-hT PCa cell line. We observed that
migration of E006AA-hT cells was inhibited by nearly 50% by NB1207 compared to a scramble
control sequence (NB1), whereas the commercially available miR-1207-3p mimic had no effect
on E006AA-hT (Figure 4.8A). Using the MTT cell proliferation assay, we observed that
proliferation of E006AA-hT CRPC cells was inhibited by nearly 40% by NB1207 compared to
NB1, while the commercially available miR-1207-3p mimic had no effect on E006AA-hT (Figure
4.8B). Therefore, the results demonstrate that NB1207 significantly inhibited cellular proliferation
in CRPC. Lastly, using Annexin V assay to assess effect on apoptosis in E006AA-hT CRPC cells,
we observed that apoptosis was increased by 2-fold in E006AA-hT cells by NB1207 compared to
NB1, while the commercially available miR-1207-3p mimic had no effect (Figure 4.8C). In
conclusion, we discovered that NB1207 more effectively inhibited migration, inhibited
proliferation and increased apoptosis in the CRPC cell line E006AA-hT PCa with increased cMYC expression when compared to the commercially available miR-1207-3p mimic. These data
also demonstrate that the miR-1207-3p/FNDC1/FN1/AR pathway regulates c-MYC in CRPC.
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Figure 4.8: NB1207 significantly inhibits migration, inhibits proliferation and induces apoptosis in
CRPC cells. Transfection of NB1 or NB1207 for 24 hours in the CRPC cell line E006AA-hT. (A) Wound
healing assay was performed to assess effect on migration. (B) MTT assay was performed to assess effect
on proliferation. (C) Annexin V assay was performed to assess effect on apoptosis. Results are presented
as mean + standard error of the mean (SEM). *P<0.05 compared to the control.

NB1207 and NB5 are more effective in inhibiting proliferation and inducing apoptosis in
CRPC cells compared to enzalutamide, abiraterone and apalutamide.
Based on consistent and highly reproducible data demonstrating underexpression of miR-12073p in CRPC cells, we hypothesized that strategies to provide exogenous miR-1207-3p may have
therapeutic effect in CRPC. Current anti-androgen therapies have concentrated on the androgendependent activation of AR through its ligand-binding domain (LBD)20,115,118. However, recent
studies have reported that AR-Vs which lack the LBD are resistant to these anti-androgen
therapies. Collectively, both ligand-dependent full-length AR (AR-FL) and AR-Vs regulate
distinctive transcriptional strategies in CRPC20,115,118. Therefore, preventing/treating
antiandrogen resistance is a major clinical challenge. It is already known that the detection of
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AR-V7 in PCa CTCs has been correlated with CRPC and resistance against enzalutamide and
abiraterone20,115,118. Consequently, we assessed the effects of miR-1207-3p on both the ligandinduced activities of full-length AR and a constitutively active truncated AR lacking the LBD,
AR-V7 in the CRPC cell line 22Rv1. To determine whether differences in AR-V7 protein levels
was a result of miR-1207-3p expression and to compare the effect NB1207 and NB5 to
abiraterone, enzalutamide and apalutamide, we examined protein levels of endogenous AR-V7 in
the CRPC cell lines, C4-2B and 22Rv1. As indicated by Figure 4.7A, treatment of C4-2B and
22Rv1 with NB1207 and NB5 dramatically reduced AR-V7 protein expression levels by more
than 50% compared to the negative controls. Furthermore, in the aggressive CRPC cell line C42B, NB1207 and NB5 more effectively inhibited AR-V7 compared to abiraterone, enzalutamide
and apalutamide by ~40%, ~35% and ~25%, respectively (Figure 4.9A). Similarly, in 22Rv1,
NB1207 and NB5 more effectively inhibited AR-V7 compared to abiraterone, enzalutamide and
apalutamide by ~50%, ~60% and ~30%, respectively (Figure 4.9A). Taken together, these
results demonstrate the specific reduction of AR-V7 levels by synthetic analogs of miR-1207-3p
is evident in CRPC models which express AR-V7.

Next, we compared the efficacy of NB1207 and another novel synthetic miR-1207-3p analog
(NB5, patent pending) with the efficacy of current anti-AR therapies abiraterone, enzalutamide
and apalutamide on proliferation and apoptosis in CRPC cells which express both AR and AR-Vs.
We first compared the efficacy in the androgen-sensitive LNCaP and E006AA PCa cell lines.
Abiraterone, enzalutamide and apalutamide blocked cell proliferation as effectively as NB1207
and NB5 in the non-CRPC LNCaP (~40%) and E006AA (~30%) PCa cell lines assessed by MTT
assay (Figure 4.9B-C). Next, we again compared the effectiveness of NB1207 and NB5 to
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enzalutamide, abiraterone and apalutamide on proliferation of the CRPC cell lines, C4-2B,
E006AA-hT, PC-3 and 22Rv1 by MTT assay. We observed that in the CRPC cell lines,
enzalutamide, abiraterone and apalutamide failed to significantly inhibit cell proliferation (Figure
4.9D-G). However, both NB1207 and NB5 significantly inhibited the proliferative effect in C42B (~50%), E006AA-hT (~50%), PC-3 (~40%), and in 22Rv1 (~50%) (Figure 4.9D-G).

To confirm the observations observed by MTT assay in the CRPC cell lines, we performed the
Click-iT EdU Alexa Flour 488 imaging assay. For the C4-2B and 22Rv1 CRPC cell lines, we
observed that EdU positive cells were reduced by nearly 70% by both NB1207 and NB5 compared
to the negative controls, while enzalutamide, abiraterone and apalutamide led to a 20%-30%
decrease in proliferation (Figure 4.9H-I). As indicated in Figure 4.7H-I, NB1207 and NB5
demonstrated more than 2-fold decrease in cellular proliferation in CRPC cells compared to
enzalutamide, abiraterone and apalutamide.

To examine whether NB1207 and NB5 overcomes the resistance to androgen antagonist therapy
in CRPC cells in part by inducing cellular apoptosis, C4-2B and 22Rv1 cells were tested using
Annexin V assay. We observed that NB1207 and NB5 increased apoptotic activity by more than
7-fold in both CRPC cell lines when compared to the negative controls (Figure 4.10A-B). More
importantly, NB 1207 and NB5 were >20% more effective in increasing apoptotic activity
compared to enzalutamide, abiraterone and apalutamide in C4-2B cells (Figure 4.10A). NB1207
and NB5 demonstrated even further superiority in 22Rv1 cells, as they demonstrated
approximately 2-fold increase in apoptotic activity compared to enzalutamide, abiraterone and
apalutamide (Figure 4.10B). Taken together, both NB1207 and NB5 inhibited proliferation and
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increased apoptosis in CRPC cell lines which express both the androgen inducible AR-FL and the
constitutively active truncated AR lacking the LBD (AR-V7).
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Figure 4.9. NB1207 and NB5 inhibits AR-V7 expression and is more effective in inhibiting
proliferation in CRPC cells compared to abiraterone, enzalutamide, and apalutamide. (A)
Comparison of effect of transfection NB1207 and NB5 on AR-V7 protein expression compared to
negative controls or abiraterone, enzalutamide and apalutamide in CRPC cell lines. MTT assay was
performed to assess effect on cell viability. (B-G) Transfection of no transfection mix, DMSO, NB1,
NB2, NB3, NB4, NB5, NB1207, enzalutamide, abiraterone or apalutamide for 24 hours in the nonaggressive cell lines LNCaP and E006AA (B-C) and the CRPC cell lines C4-2B, E006AA-hT, PC-3 and
22RV1 (D-G). EdU assay was performed to assess effect on cell proliferation. (H-I) Transfection of no
transfection mix, DMSO, NB1, NB2, NB3, NB4, NB5, NB1207, enzalutamide, abiraterone or
apalutamide for 24 hours in the CRPC cell lines C4-2B and 22Rv1.

Figure 4.10. NB1207 and NB5 are more effective in inducing apoptosis in CRPC cells compared to
enzalutamide, abiraterone and apalutamide. Annexin V assay was performed to assess effect on cell
apoptosis. (A-B) Transfection of no transfection mix, DMSO, NB1, NB2, NB3, NB4, NB5, NB1207,
enzalutamide, abiraterone or apalutamide for 24 hours in the CRPC cell lines C4-2B and 22Rv1. Results
are presented as mean + standard error of the mean (SEM). *P<0.05 compared to the control.
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Discussion

Men with advanced disease typically receive androgen deprivation therapy (ADT) with new
second-generation therapeutic agents such as enzalutamide or abiraterone17,120. Yet, it is well
established that these patients who receive ADT inescapably succumb to their relapsed tumor after
a period where the disease is in remission11,17,103. As PCa is a heterogeneous disease, the chief
obstacle is understanding the molecular mechanisms involved in this progression from the
asymptomatic androgen-dependent PCa to the lethal CRPC. Consequently, new biomarkers and
treatment strategies are urgently required to combat CRPC.

This is the first report to show that miR-1207-3p regulates c-MYC expression via the miR-12073p/FNDC1/FN1/AR pathway in aggressive PCa. c-MYC is a vital transcription factor and a crucial
protein, and direct targeting may have severe consequences on patients72-75,79,121. Because c-MYC
targeting has proved difficult, our data demonstrating the regulation of c-MYC expression by the
miR-1207-3p/FNDC1/FN1/AR pathway bears significant implications for treatment of c-MYCdriven cancers. Excitingly, targeting miR1207-3p may be less challenging and the effects may be
less deleterious than targeting c-MYC itself for inhibiting c-MYC driven cancers72-75,79,121. Our
findings have illuminated the molecular details of miR-1207-3p/c-MYC cooperation and the
synthesis of the novel NB1207 and NB5 as candidate therapeutics specifically targeting the miR1207-3p/FNDC/FN1/AR/c-MYC pathway in CRPC.

We have also demonstrated the potential diagnostic and prognostic value of miR-1207-3p in
CRPC. Currently, the Gleason grading system represents an invasive technique which evaluates
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the prognosis of men with PCa using samples from a prostate biopsy. From the perspective of
personalized medicine, an improved strategy for better patient stratification and treatment response
should include the monitoring of specific miRNAs5,25,34,122. Various studies have established the
stability of miRNAs in serum, plasma and urine as well as the differential expression of miRNAs
in normal and tumor tissue which demonstrates the potential of miRNAs as potential PCa
biomarkers and predictors of therapy response2,5,7,43. Accordingly, our prostate tissue analysis
revealed that underexpression of miR-1207-3p and the overexpression of FNDC1, FN1, AR and
c-MYC are significantly associated with aggressive PCa. Furthermore, we observed that miR1207-3p, FNDC1, FN1, AR and c-MYC were significantly differentially expressed between
benign prostatic hyperplasia and PCa. Also, miR-1207-3p was underexpressed while c-MYC was
overexpressed in tumors with Gleason score ≥8 in comparison to those with Gleason score <8.
These findings demonstrate the potential usefulness of miR-1207-3p and c-MYC for PCa risk
stratification.

The observation of decreased miR-1207-3p expression during PCa progression indicates that
strategies to enhance miR-1207-3p in PCa may have therapeutic value in CRPC. miRNAs can
simultaneously modulate several cancer-relevant gene pathways and can be exploited to increase
the sensitivity of tumor cells to conventional anticancer agents5,7,27,34,39,44,122,123. Because of this
potential to be one-hit multi-target therapeutic agents against PCa, miRNAs are interesting
therapeutic candidates27,34,123,124. We observed that the novel candidate therapeutic, NB1207,
significantly inhibited c-MYC protein expression in the CRPC cell lines. Furthermore, NB1207
significantly inhibited migration, inhibited proliferation and induced apoptosis in CRPC cell lines.
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Therefore, these in vitro studies demonstrate the potential of miR-1207-3p analogs, such as
NB1207 and NB5 serving as therapeutics for CRPC.

Consequently, we investigated if NB1207 and NB5 could have efficacy against CRPC cells that
have proven to be resistant to both first generation and second generation ADTs. The notion that
those PCas continuing to progress during ADT are androgen independent has been reconsidered
in the last few years and it is now accepted that AR signaling plays a significant role in CRPC
despite castrate-levels of testosterone17,103,105,122. Important advances in the understanding of the
mechanism involved in CRPC pathogenesis have led to welcome breakthrough of several ARtargeting drugs such as abiraterone, enzalutamide and apalutamide17,125-129. However, despite their
promising effects in some patients with CRPC, approximately 20-40% of patients do not benefit
from these agents and eventually all the initial responders to these drugs acquire secondary drug
resistance leading to death115,118. Recent studies have reported that AR-Vs signal in the absence of
the ligand binding domain (LBD) which are a crucial contributing factor for resistance to LBDtargeting AR antagonists or agents that repress androgen biosynthesis such as abiraterone,
enzalutamide and apalutamide20,115,118. Among the variants, AR-V7 is the most studied member
because it is the only known variant of which the encoded endogenous protein is detectable in
clinical specimens20,28,115. Studies have shown a strong association between the presence and
overexpression of AR-V7 in CRPC and resistance to the current drug regimen20,28,115,116. This
resistance is a major clinical challenge in the field and a clearer understanding of the mechanisms
underlying resistance to these drugs would facilitate selection of alternative novel therapeutic
strategies20,28,115. Consequently, we have demonstrated that NB1207 and NB5 significantly
inhibited AR-V7 protein expression in the CRPC models, C4-2B and 22Rv1.
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In that regard, the efficacy of our novel candidate therapeutics, NB1207 and NB5, against CRPC
cells is of tremendous interest. We discovered that NB1207 and NB5 is as effective as abiraterone,
enzalutamide and apalutamide in significantly preventing proliferation and increasing apoptotic
activity in non-CRPC cell lines. Strikingly, our results demonstrate significant anti-proliferative
and pro-apoptotic effects of NB5 and NB1207 in CRPC cell lines whereas abiraterone,
enzalutamide and apalutamide were less effective. Our novel miR-1207-3p/FNDC1/FN1/AR/cMYC pathway suggests that the role of AR-V7 on CRPC development and PCa progression may
be mediated in part via c-MYC. Moreover, NB5 and NB1207 may be promising therapeutic agents
against AR-V7 expressed CRPC by serving as c-MYC inhibitors. Based on our data, it is likely
this may be less susceptible than all current ADTs to the development of resistance in advanced
PCa28,115.

In conclusion, this is the first report to show the potential diagnostic and prognostic value of miR1207-3p as it has been shown to be a candidate biomarker for risk stratification. NB1207 and NB5
are efficacious in inhibition of proliferation of CRPC and increasing the apoptotic activity of
CRPC via targeting c-MYC. Overall, our results demonstrate a preclinical proof-of-principle that
NB5 and NB1207, our novel analogs of miR-1207-3p, may be promising therapeutics for the
treatment of CRPC.
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Chapter 5:
Conclusion, Significance and Future Directions
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In Chapter 1 we presented the rationale for investigating the role of miR-1207-3p in PCa.
Understanding the molecular mechanisms of PCa progression is essential for the discovery of
robust prognostic markers which we believe are capable of helping to identify those patients that
are at the greatest risk of relapse17,20,25. This will, in turn, enable us to optimize management
strategies to control PCa progression. In that light, the importance of miRNAs in cancer biology
has become apparent for the discovery of miRNA-based diagnostic, prognostic and theranostic
biomarkers7,39,43,124. Moreover, their relative stability in tissues and a variety of biofluids including
blood and urine makes repeated measurements of miRNA levels by qRT-PCR assays very
feasible8,39,124,130,131. This can provide critical information on a disease’s molecular signature status
over time through the course of treatment and recurrence without the need for a biopsy5,43.

We made several novel findings. We discovered that expression of miR-1207-3p is significantly
diminished in PCa cells1. We also demonstrated that increased expression of miR-1207-3p in PCa
cells significantly inhibits migration and proliferation, and induces apoptosis via direct molecular
targeting of FNDC11. These functional experiments clearly demonstrate a mechanism by which
miR-1207-3p regulates key cellular processes dysregulated in the development and progression of
PCa. Importantly, we describe for the first time the miR-1207-3p/FNDC1/FN1/AR novel
regulatory pathway in PCa: miR-1207-3p-induced loss of FNDC1 expression leads to the loss of
FN1 and subsequently AR expression1. Our novel pathway has important clinical implications as
miRNAs possess several key features that make them attractive PCa biomarkers33,34,43. Our clinical
results indicate that FNDC1, FN1, and AR are concurrently overexpressed in metastatic PCa1.
Also, FN1 overexpression in prostate tumors positively correlated with overall death and PCa-
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specific death1. To our knowledge this is the first description of FN1 as a potential prognostic
biomarker in human clinical PCa.

To identify the target genes of miR-1207-3p in PCa and to investigate the involvement of miR1207-3p target genes in PCa, we designed and synthesized a novel synthetic biotinylated miR1207-3p duplex (NB1207) and scramble duplex (NB1) (Patent application publication number,
US20170121711 A1). Prior to using the NB1207 for target discovery, we compared their effects
to that of the previously used commercially available miR-1207-3p mimic on the 3’UTR of
FNDC1, and PCa cell proliferation, migration and apoptosis. Of significance, we observed that
NB1207 maybe be more efficient than the commercially available mimic as NB1207 significantly
inhibited migration, inhibited proliferation and induced apoptosis in several CRPC cell lines while
the mimic had little effect. We have already used these novel tools (NB1207 and NB1) to perform
a RNA pull down assay that demonstrated that FNDC1 is a direct molecular target of miR-12073p. This gives us the confidence and the ability to identify all the molecular targets of miR-12073p. Future work will employ these tools in a RNA pulldown approach followed up with RNA
sequencing of the enriched RNA pulled down to identify all directly bound RNA molecular targets
of miR-1207-3p.

As a sub-study, we investigated the impact of racial disparity in PCa because moAA have a 2-fold
higher chance of getting aggressive PCa. Despite progress being made in the field, significant PCa
racial disparity persists82,83,109. In this regard, we discovered that miR-1207-3p is differentially
expressed in primary tumors from moAA tissues compared to primary tumors of CM. To our
knowledge, this is the first report of a microRNA that directly correlates with aggressive PCa and
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has divergent expression between CM and moAA. The discovery of a miRNA biomarker that is
capable of displaying differential expression in men of different ancestry is of great significance
for the development and optimization of miR-1207-3p-based therapeutic strategies for
personalized treatment approaches. Further studies are required to establish this.

In Chapter 4, we investigated the relationship of miR-1207-3p with the proto-oncogene, c-MYC.
Our results demonstrated that it may be possible to predict clinical behavior of PCa based upon
miRNA-1207-3p expression. Approximately 30% of PCa patients develop clinical recurrence, and
the survival period of this phase of PCa is limited and extremely variable, the challenge lies in the
identification of those patients most at risk for relapse6,12,17,25. Because c-MYC is commonly found
to be amplified in up to 72% of CRPCs, targeting c-MYC could be a potential approach against
CRPC. Yet, the mechanisms regulating c-MYC have not been fully delineated in PCa.

We discovered the underexpression of miR-1207-3p and the overexpression of FNDC1, FN1, AR
and c-MYC is associated with increased risk of cancer progression and aggressive PCa.
Investigations into miR-1207-3p ability to improve risk stratification in human clinical PCa by
determining if there are any correlation with Gleason scores demonstrated that miR-1207-3p
negatively correlates with c-MYC in tumors with Gleason score ≥8. This is of clinical significance
for several reasons. Currently, factors such as serum PSA level, Gleason score, and tumor stage
are used for diagnosis, prognostication and treatment decision-making8,132. However, none of these
alone or in combination are adequate indicators for accurate clinical decision-making6,105,133. It is
likely that heterogeneity of PCa at the molecular level may account for the fact that even those
patients displaying similar PSA levels, tumor stage, Gleason score can still have different clinical
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outcomes

6,105,133

. Furthermore, factors to detect recurrence such as increased serum PSA levels

may actually lead to false positive diagnosis124. Moreover, increased PSA following radical
prostatectomy can be caused by the presence of residual benign prostate tissue14,15,134. Considering
these current limitations, our discovery adds to the “tool-box” to improve the clinical decisionmaking process2. To our knowledge, this is the first study to evaluate the expression of miR-12073p in any human disease and the first description of miR-1207-3p differential expression in human
clinical PCa1. Importantly, this is the first report to show the potential diagnostic value of miR1207-3p as it has been shown to be a candidate biomarker for risk stratification in human clinical
PCa.

In Chapter 4, we also confirmed that c-MYC is not a direct molecular target of miR-1207-3p yet
is regulated by our pathway. Consequently, we have discovered a novel miR-12073p/FNDC1/FN1/AR/c-MYC pathway in PCa. Additionally, using miR-1207-3p analogs (NB1207
and NB5), we discovered that overexpression of miR-1207-3p more effectively inhibited
proliferation and increased apoptosis in the CRPC cell lines. Our reproducible results had
prompted us to envision miR-1207-3p as a therapeutic to help health care professionals combat
CRPC in patients. Current anti-androgen therapies including enzalutamide, abiraterone and
apalutamide are unable to inhibit proliferation and increase apoptosis in CRPC cell lines such as
C4-2B. Thus the question which remained is can our novel miR-1207-3p analogs demonstrate
efficacy in CRPC where current CRPC treatments have failed? We observed that treatment with
NB1207 and NB5 inhibited AR-V7 protein expression in CRPC cells and more significantly
inhibited proliferation and increased apoptosis of CRPC cells compared to abiraterone,
enzalutamide and apalutamide. These results demonstrate that use of synthetic analogs of miR-

74

1207-3p such as NB5 and NB1207 may be a novel strategy for successful therapeutic targeting of
c-MYC in CRPC.

In summary, we present mechanistic and clinical data characterizing the novel miR-12073p/FNDC1/FN1/AR/c-MYC molecular pathway suggesting its role in PCa (Figure 5.1)1. We
conclude that the present study signifies that miR-1207-3p may have potential diagnostic,
prognostic, and therapeutic applications in PCa. Furthermore, our results demonstrate proof-ofprinciple that NB1207 and NB5 may be promising therapeutics for the treatment of CRPC.

Figure 5.1: miR-1207-3p/FNDC1/FN1/AR/c-MYC is a novel regulatory pathway in PCa.
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